

REPORT OF THE 381st CELL EXCHANGE

JUNE 24, 2014

B-cell Lines	501-504
Cells	1521-1524
Serum	1145-1152

B-cell Line Exchange #251

The results for B-cell Line Exchange #251 are summarized on Tables 1-2 and individual laboratory results reported for each cell are listed in Tables 3-6. The haplotype frequencies used in this report are from the NMDP Bio-

informatics website, <http://bioinformatics.nmdp.org/>. We wish to express our appreciation to **Franz Claas, Leiden University Medical Center, Leiden, The Netherlands**, for sharing the interesting cells examined in our studies.

Ter-501. The consensus type for this Caucasian sample is DRB1*04:07-DRB1*11:09-DRB3*02:02-DRB4*01:03-DQA1*03:03-DQA1*05:05-DQB1*03:01-DPA1*01:03-DPB1*03:01-A*02:01-B*44:02-B*51:01-C*07:04-C*14:02. One likely haplotype in this cell may be DRB1*04:07-DRB4*01:03-DQA1*03:03-DQB1*03:01, as observed in Ter-410 (same as Ter-296, 230). The other likely haplotype is DRB1*11:09-DRB3*02:02-DQA1*05:05-DQB1*03:01. The DRB1*11:09-DQB1*03:01 association in this cell is observed exclusively in Caucasians, with HF= 0.00006.

This cell is BEL7MON, the reference cell for DRB1*11:09 (1). It was previously typed as Ter-407 (2008) and Ter-328 (2003), as noted by Lopez-Cepero, Rao, and Tiercy. This cell was also typed as DNA #513 in the International HLA DNA Exchange in 2007. In this present retyping, Renac, along with Turner and Arnold, detected the presence of a possible new C-locus allele. Turner and Arnold kindly shared their findings, "SBT of C locus has A/C at pos. 1040 (codon 323) in exon 6, which is a mismatch for the C*07:04:01, 14:02:01 pair. Both C*07:04:01 and C*14:02:01 have an "A" at this pos. This changes the amino acid from a Q to P for one of the alleles, although we cannot determine phase. So, there is a new allele, and because it changes the amino acid in an exon, it would be a new C*07 or C*14 (C*07:04:01, C*14:new OR C*07:new, C*14:02:01). The new allele would still fall into the same P group, (C*07:04P, 14:02 OR C*07:04, 14:02P), because the base change occurs outside the antigen recognition site (exons 2 & 3). The most common type given on both SSO and SSP

was C*07:04, 14:02." The new C-locus allele was first reported in the 2007 International HLA DNA Exchange study by 2 SBT labs. Using 4 GSSP primers, 1 of those labs confirmed the new polymorphism as belonging to C*07 (2).

Ter-502. The consensus type for this Caucasian sample is DRB1*07:01-DRB1*11:19-DRB3*02:02-DRB4*01:03-DQA1*02:01-DQA1*05:05-DQB1*02:02-DQB1*03:01-DPA1*01:03-DPB1*02:01-DPB1*04:01-A*02:01-A*24:02-B*07:02-B*13:02-C*06:02-C*07:02. One likely haplotype in this cell is DRB1*07:01-DRB4*01:03-DQA1*02:01-DQB1*02:02, as observed in Ter-426 (same as Ter-219, 281) and Ter-427 (same as Ter-307). The other probable haplotype is DRB1*11:19-DRB3*02:02-DQA1*05:05-DQB1*03:01, as observed in Ter-483 (same as Ter 298, 278, 217).

This cell was previously typed as Ter-408 (2008) and Ter-297 (2002), as correctly identified by Lopez-Cepero and Tiercy. It was also typed in the International HLA DNA Exchange as DNA #514 (2007). In this present retyping, there was improved agreement among the labs in the assignments of DQB1*03:01 and DQA1*05:05, with the detection level of each increasing from 36% in 2008 to 49% and 46%, respectively. DRB1*11:19 was reported by 68%, with 6 labs assigning DRB1*11:19:01. DRB1*07:01 (53%) was reported as the second DRB1 type, with 5 labs assigning DRB1*07:01:01.

B-cell Line Exchange #252

The results for B-cell Line Exchange #252 are summarized on Tables 7-8 and individual laboratory results reported for each cell are listed in Tables 9-12.

We are grateful to the generosity of **Helen Bass, Jane Rowlands, and Tracy Rees, Welsh Blood Service, Pontyclun**, for providing us with the valuable reference cells examined in our Exchanges.

Ter-503. The consensus type for this sample is DRB1*03:01-DRB1*13:29-DRB3*02:02-DRB3*03:01-DQA1*01:02-DQA1*05:01-DQB1*02:01-DQB1*06:04-DPA1*01:03-DPB1*02:02-DPB1*03:01-A*26:01-A*30:02-B*18:01-B*40:01-C*03:04-C*05:01. One likely haplotype in this cell is DRB1*03:01-DRB3*02:02-DQA1*05:01-DQB1*02:01, as observed in a number of previous exchange cells, most recently Ter-484 (same as Ter-436, 327). The other probable haplotype is DRB1*13:29-DRB3*03:01-DQA1*01:02-DQB1*06:04.

This cell is TER320, the reference cell for DRB1*13:29, as astutely noted by Tiercy. It was previously typed as Ter-320 (2003) and Ter-395 (2007), as correctly identified by Dunn, Lopez-Cepero, Rao, and Tiercy. This cell was also typed in the International HLA DNA Exchange as DNA #502 (2006). In this present retyping, DRB1*13:29 was assigned by 65%, a decrease from its assignment by 71% in 2007. By contrast, the detection of DPB1*03:01 improved from a detection level of 40% in 2007 to 66%, in this present typing. DPB1*03:01/*104:01 was reported by 6 labs.

Ter-504. The consensus type for this sample of mixed Japanese and Black heritage is DRB1*13:01-DRB1*15:02-DRB3*02:02-DRB5*01:02-DQA1*01:03-DQB1*06:01-DQB1*06:08-DPA1*02:01-DPA1*03:01-DPB1*09:01-DPB1*105:01-A*24:02-A*68:02-B*47:03-B*52:01-C*07-C*12:02. One likely haplotype in this cell is DRB1*15:02-DRB5*01:02-DQA1*01:03-DQB1*06:01, as observed in the workshop cell IHW9327 (same as Ter-425 and Ter-332). The other likely haplotype may be DRB1*13:01-DRB3*02:02-DQA1*01:03-DQB1*06:08. The DRB1*13:01-DQB1*06:08 association in this cell is commonly observed in African American populations, with HF=0.00093.

This cell is 29182, the reference cell for B*47:03 (3). It was previously typed as Ter-389 in 2007, as correctly identified by Lopez-Cepero, Rao, and Tiercy. It was also typed for class I as extracts 392 (2007) and 462 (2009), as astutely noted by Dunn. In this present retyping, 66% of labs assigned B*47:03 compared to 61% in 2009. The detection of DPB1*105:01 (formally DPB1*06:02) also improved. In 2009, DPB1*06:02 was assigned by 41%, with an additional 7 labs assigning DPB1*04:02/*06:02. In this retyping, 83% assigned DPB1*105:01, showing improved standardization for this allele.

References:

1. Williams F, Hughes DJ, and Middleton D. A new HLA-DRB1*11 allele (DRB1*1109) differing at codons 32, 34 and 37. *Tissue Antigens* 1994;44:63-64.
2. Muramoto J, Cecka JM, Reed EF. Summary of the 32nd International HLA DNA Exchange 2007.
3. Darke, C, Guttridge, MG, Street, J, et al. HLA-B*4703: sequence confirmation, serology and distribution. *Tissue Antigens* 199;53:586-590.

Table 1: Summary of the 251st B-cell Line Exchange

Ter-501													
DNA Typing - class II	61 LABS - DRB1 %(n)		39 LABS - DRB3		33 LABS - DQA1 %(n)		58 LABS - DQB1 %(n)		13 LABS - DPA1 %(n)		29 LABS - DPB1 %(n)		
	DRB1*04:07:01	3 (2)	DRB3*02:02	35(14)	DQA1*03:03:01	3 (1)	DQB1*03:01:01G	2 (1)	DPA1*01:03:01G	8 (1)	DPB1*03:01:01	7 (2)	
	DRB1*04:07:01G	5 (3)	DRB3*02:02+	21(8)	DQA1*03:03	40(13)	DQB1*03:01:01	3 (2)	DPA1*01:03	69(9)	DPB1*03:01:01G	7 (9)	
	DRB1*04:07	24(15)	DRB3*02	21(8)	<i>DQA1*03:01</i>	3 (1)	DQB1*03:01	45(26)	<i>DPA1*01:09</i>	8 (1)	DPB1*03:01P	10(3)	
	<i>DRB1*04:102</i>	2 (1)	DRB3*+	23(9)	DQA1*03:02/03	30(10)	DQB1*03:01+	14(8)	DPA1*01	15(2)	DPB1*03:01	55(16)	
	DRB1*04:07+	33(20)			DQA1*03	24(8)	DQB1*03(DQ7)	3 (2)			DPB1*03:01/*104:01	17(5)	
	DRB1*04	33(20)					DQB1*03	33(19)			DPB1*03	4 (1)	
	DRB1*11:09	57(35)	39 LABS - DRB4		DQA1*05:05:01G	3 (1)							
	<i>DRB1*13:05</i>	2 (1)	DRB4*01:03	44(17)	DQA1*05:05	40(13)							
	DRB1*11:09+	7 (4)	DRB4*01:01/03/06	10(4)	DQA1*05:05+	33(11)							
	DRB1*11	34(21)	DRB4*01	23(9)	DQA1*05	24(8)							
			DRB4*+	23(9)									
Serology - class II	5 LABS - DR %(n)		DR52		5 LABS - DQ %(n)		DQ7		80(4)				
	DR4	100(5)			DQ3		20(1)						
	DR11	100(5)	DR53	100(5)					DQ3		60(3)		
									DQ8		20(1)		
								DQ2		20(1)			
DNA Typing - class I	35 LABS - HLA-A %(n)		35 LABS - HLA-B %(n)		35 LABS - HLA-C %(n)								
	A*02:01:01:01	3 (1)	B*44:02:01G	6 (2)	C*07:04:01	3 (1)							
	A*02:01:01	6 (2)	B*44:02	28(10)	C*07:04:01G	6 (2)							
	A*02:01:01G	3 (1)	B*44:02+	17(6)	C*07:04	23(8)							
	A*02:01	34(12)	B*44	49(17)	C*07:04+	20(7)							
	A*02:01+	11(4)			C*07	49(17)							
	A*02	43(15)											
			B*51:01:01G	3 (1)	C*14:02:01	6 (2)							
			B*51:01	37(13)	C*14:02:01G	3 (1)							
			B*51:01+	11(4)	C*14:02	28(10)							
			B*51	49(17)	C*14:13	3 (1)							
					C*14:02+	11(4)							
					C*14	49(17)							

Table 2: Summary of the 251st B-cell Line Exchange

Ter-502

DNA Typing - class II		38 LABS - DRB3		33 LABS - DQA1		57 LABS - DQB1		13 LABS - DPA1		28 LABS - DPB1	
60 LABS - DRB1	%(n)	DRB3*02:02	37(14)	DQA1*02:01	85(28)	DQB1*02:02:01	3 (2)	DPA1*01:03:01G	8 (1)	DPB1*02:01:02	11(3)
DRB1*07:01:01	8 (5)	DRB3*02:02+	21(8)	DQA1*02	12(4)	DQB1*02:02	51(29)	DPA1*01:03	77(10)	DPB1*02:01:02G	4 (1)
DRB1*07:01:01G	2 (1)	DRB3*02	21(8)	DQA1*03	3 (1)	DQB1*02:02+	12(7)	DPA1*01	15(2)	DPB1*02:01P	7 (2)
DRB1*07:01	43(26)	DRB3*+	21(8)			DQB1*02	32(18)			DPB1*02:01	61(17)
DRB1*07:01+	7 (4)					DQB1*03	2 (1)			DPB1*02:01/*141:01	11(3)
DRB1*07	40(24)									DPB1*02:01/+	3 (1)
										DPB1*02	3 (1)
DRB1*11:19:01	10(6)	38 LABS - DRB4		DQA1*05:05:01G	3 (1)	DQB1*03:01:01	3 (2)			DPB1*04:01:01	7 (2)
DRB1*11:19	58(35)	DRB4*01:03	45(17)	DQA1*05:05	43(14)	DQB1*03:01:01G	2 (1)			DPB1*04:01:01G	7 (2)
DRB1*11	32(19)	DRB4*01:01/03/06	10(4)	DQA1*05:05+	27(9)	DQB1*03:01	44(25)			DPB1*04:01P	4 (1)
		DRB4*01	24(9)	DQA1*05	27(9)	DQB1*03:01+	16(9)			DPB1*04:01	75(21)
		DRB4*+	21(8)			DQB1*03(DQ7)	3 (2)			DPB1*04:01/*149:01	4 (1)
						DQB1*03	32(18)			DPB1*04	4 (1)

Serology - class II		5 LABS - DR		5 LABS - DQ	
5 LABS - DR	%(n)	DR52	100(5)	5 LABS - DQ	%(n)
DR7	100(5)			DQ2	100(5)
DR11	100(5)	DR53	100(5)	DQ7	80(4)
				DQ3	20(1)

DNA Typing - class I		34 LABS - HLA-A		34 LABS - HLA-B		34 LABS - HLA-C	
34 LABS - HLA-A	%(n)	34 LABS - HLA-A	%(n)	34 LABS - HLA-C	%(n)	C*06:02:01:01	3 (1)
A*02:01:01	6 (2)	B*07:02:01	3 (1)	C*06:02:01G	6 (2)	C*06:02	23(8)
A*02:01:01G	3 (1)	B*07:02:01G	6 (2)	C*06:11	3 (1)	C*06:02+	21(7)
A*02:01	32(11)	B*07:02	21(7)	C*06	44(15)		
A*02:01+	18(6)	B*07:02+	23(8)			C*07:02:01	3 (1)
A*02	41(14)	B*07	47(16)			C*07:02:01G	6 (2)
						C*07:02	23(8)
						C*07:02+	23(8)
						C*07	44(15)
A*24:02:01G	3 (1)	B*13:02:01	6 (2)				
A*24:02	41(14)	B*13:02:01G	3 (1)				
A*24:02+	15(5)	B*13:02	32(11)				
A*24	41(14)	B*13:02+	12(4)				
		B*13	47(16)				

Table 3: Individual laboratory results for B-cell #501-Class II

Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1	METHOD
5488	Adams, Sharon	*04:07:01/92	*11:09	*02	*01	*03:03	*05:05	*03:01:01			*03:01:01	SSO, SBT, SSP
4691	Ajlan, Abdula	*04:07/92	*11:09					*03:01/27/28+	*03:01/24+			SSO, SBT
8038	Cao, Kai	*04:07/92	*11:09	*02:02/28/29N	*01:01/03/06	*03:02/03	*05:05/09/11	*03:01:01		*01:03	*03:01/*104:01	SSO, SSP, SBT
774	Cecka, J. Mich	*04:07/92/129	*11:09	*02:02/26/28+	*01:03	*03:03	*05:05/11	*03:01/17/21+				SSO, SSP
8070	Chang, Uckjin	*04	*11									P-SSP
9916	Charlton, Ron	*04:07:01	*11:09	*02:02	*01:03			*03:01/75/76+				SSP, SBT
9916	Charlton_LR	*04	*11	*+	*+			*03				SSP, SBT
4492	Charron, D.	*04:07/92	*11:09	*02:02	*01:03	*03:02/03	*05:05/09/11	*03:01/75/76+		*01:03	*03:01/*104:01	P-SSO, SSP
8021	Clark, Brenda	*04:07	*11:09	*02:02+	*01			*03:01			*03:01	P-SSP, RVSSO
3632	Colombe, Beth	*04:07	*11:09	*02:02	*01:03	*03:03	*05:05	*03:01				SSOP, SSP
5130	Costeas, Paul	*04:07	*13:05	*02:02	*01:03	*03:03	*05:05	*03:01				SSO, SSP
779	Daniel, Claud	*04:07/92/129	*11:09/28	*02	*01	*03:03	*05:05	*03:01		*01:03	*03:01	P-SSP, SSO
5219	Daniel, Dolly	*04	*11					*03	*03			P-SSOP, P-SSP
5891	Du, Keming	*04:07/92	*11:09					*03:01	*03:01			P-SBT
3766	Dunn, Paul	*04:07/92/129	*11:09	*+	*+	*03:02/03	*05:05/09/11	*03		*01	*03:01	RT-PCR, SSO
5214	Eckels/CPMC	*04	*11	*02	*01	*03	*05	*03 (DQ7)		*01:03	*03:01P	SSOP
3135	Enczmann, J	*04:07	*11:09	*02:02	*01:03			*03:01			*03:01	SBT, P-SSP, P-SSO
762	Fischer, Got	*04:07/92	*11:09	*02:02/28	*01:03	*03:03	*05:05	*03:01/19			*03:01/*104:01	SSO, SBT
4079	Fort, Marylis	*04	*11					*03			*03:01	SSP
792	Gandhi, Manis	*04:07	*11:09	*02:02	*01:03	*03:03	*05:05	*03:01			*03:01	SSO, SSP
8043	Gideoni, Osna	*04:07	*11:09			*03:03	*05:05	*03:01		*01:03	*03:01	SSP
9002	Gideoni_LR	*04	*11					*03				SSO
910	Hahn, Amy B.	*04	*11	*+	*+	*03:03	*05:05	*03	*03			SSP
2344	Hurley/Hartz	*04:07:01G	*11:09			*03:03:01	*05:05:01G	*03:01:01G	*03:01:01G	*01:03:01G	*03:01:01G	SBT, SSOP
771	Israel, Shosh	*04:07	*11:09					*03:01				SSP
9003	Israel_LR	*04	*11					*03				
794	Jaatinen, Tai	*04:07/92	*11:09	*02:02	*01:03	*03:02/03	*05:05/09/11	*03:01		*01:03	*03:01/*104:01	SBT, SSO, SSP
8086	Jie, Pan	*04:07/92	*11:09			*03:03	*05:05	*03:01	*03:01		*03:01	
2847	Kihara, Masaaki	*04	*11									RVSSO
4337	Kim, Tai-Gyu	*04:07	*11:09					*03:01			*03:01	SBT
1694	Kissel&Hess	*04	*11	*+	*+			*03:01				SSP
168	Klein, Tirza	*04:07	*11:09					*03:01				P-SSO, SSP
9000	Klein_LR	*04	*11					*03				P-SSO, SSP
87	Land, Geoffre	*04:07	*11:09	*02:02	*01:03	*03:03	*05:05	*03:01	*03:01		*03:01	SBT, SSO, SSP
725	Lardy, N, M.	*04	*11	*+	*+	*03	*05	*03				SSO, SSP
278	Lee, Jar-How	*04:07	*11:09	*02:02	*01:03	*03:03	*05:05	*03:01		*01:03	*03:01	SSP, RVSSOP
6649	Lim, Young Ae	*04	*11	*+	*+							SSP
274	Lo, Raymundo	*04:102	*11			*03	*05	*03	*03	*01:09	*03:01	SSO
759	Lopez-Cepero	*04:07/92	*11:09/28	*02:02/27/28	*01:01/03/06	*03:02/03	*05:05/09	*03:01/24/27+		*01:03	*03:01P	RVSSO
8029	Mani, Rama	*04	*11					*03	*03			SSO
8052	Marcos, Cintia Y	*04:07/92/129	*11:09/28			*03:02/03	*05:05/09/11	*03	*03			P-SSO
206	McAlack-Hana	*04	*11	*02	*01	*03	*05	*03 (DQ7)	*03 (DQ7)			RVSSOP

Table 3: Individual laboratory results for B-cell #501-Class II

Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1	METHOD
8042	Muncher,Lior	*04:07	*11:09					*03:01				SSO,SSP
9001	Muncher_LR	*04	*11					*03				SSO,SSP
54	Pancoska,Ca	*04	*11	*02	*01	*03	*05	*03		*01:03	*03	RVSSO
3966	Permpikul&Ve	*04:07	*11:09	*02:02	*01:03			*03:01				P-SSP
2400	Phelan,Donna	*04:07/92	*11:09	*02	*01	*03:02/03	*05:05/09/11	*03:01			*03:01/*104:01	SSO,SBT,SSP
8001	Rao,Prakash	*04:07	*11:09	*02:02	*01:03	*03	*05	*03:01			*03:01	RVSSO,SSP
3753	Reed,Elaine	*04:07/92	*11:09	*02:02/27/28+	*01:01/03/06	*03:02/03	*05:05/09/11	*03:01	*03:01			SBT,SSO
3519	Renac,Virginie	*04:07/92	*11:09	*02:02	*01:03	*03:01	*05:05	*03:01			*03:01	SBT,P-SSP
3519	Renac,Virginie_LR	*04	*11					*03			*03:01	P-SSP
1160	Rosen-Bronson	*04:07/92/129	*11:09/28	*02	*01			*03				SSO
4251	Schiller,J	*04:07:01G	*11:09	*02:02/27/28+	*01:01/03/06	*03	*05	*03:01	*03:01	*01	*03:01:01G	P-RVSSO,SBT
8068	Shanmugam,He	*04	*11	*+	*+			*03				P-SSP
1108	Sutherland,L	*04	*11	*02	*01	*03	*05	*03	*03			SSOP
747	Tiercy,Jean-	*04:07:01	*11:09	*02:02	*01:03	*03:02/03	*05:05/09/11	*03:01			*03:01:01	SSO,SSP,SBT
5451	Tilanus,Marc	*04:07:01	*11:09	*+	*+			*03				SBT,SSP
5462	Turner,E.V.	*04:07/92	*11:09	*02:02/28/29N	*01:03			*03:01			*03:01P	SSP,SSO,SBT
5642	Varnavidou-N	*04:07/92	*11:09	*+	*+			*03:01/21/22	*03:01/17+			P-SSP
797	Yabe,Hiromasa	*04:07/92	*11:09			*03:02/03	*05:05/09	*03:01/24/27+				SSO
3511	Zeevi,Adrian	*04:07	*11:09	*02:02	*01:03	*03:03	*05:05	*03:01			*03:01	RVSSOP,SSP

CTR	DIRNAME	DR4	DR11	DR52	DR53			DQ7	DQ3	OTH1	OTH2
4492	Charron,D.	+	+	+	+			+	+		
910	Hahn,Amy B.	+	+	+	+			+	DQ8		
4908	Kvam,Vonnett	+	+	+	+			+		DQ2	
54	Pancoska,Car	+	+	+	+			DQ3	+		
793	Rubocki,Rona	+	+	+	+			+	+		

Table 4: Individual laboratory results for B-cell #501-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*02:01:01		*44	*51	*07	*14	SSO, SBT, SSP
4691	Ajlan, Abdula	*02:01	*02:01	*44	*51	*07:04	*14:02	SSO, SBT
8038	Cao, Kai	*02:01:01		*44:02	*51:01	*07:04/11	*14:02:01	SSO, SSP, SBT
774	Cecka, J. Mich	*02		*02:02/26/28+	*51	*07	*14	SSO, SSP
9916	Charlton, Ron	*02:01:01:01		*44:02	*51:01	*07:04:01	*14:02:01	SSP, SBT
9916	Charlton_LR	*02		*44	*51	*07	*14	SSP, SBT
4492	Charron, D.	*02:01/01L/97+		*44:02/173	*51:01/142	*07:04	*14:02/23/31/50/51	P-SSO, SSP
8021	Clark, Brenda	*02:01+		*44:02+	*51:01+	*07:04+	*14:02+	P-SSP, RVSSO
5130	Costeas, Paul	*02:01		*44:02	*51:01/86/91/95	*07:04	*14:02	SSO, SSP
5219	Daniel, Dolly	*02	*02	*44	*51	*07	*14	P-SSOP, P-SSP
5891	Du, Keming	*02:01	*02:01	*44:02/19N	*51:01	*07:04/11/181	*14:02/13	P-SBT
3766	Dunn, Paul	*02		*44	*51	*07	*14	RT-PCR, SSO
3135	Enczmann, J	*02:01/01L		*44:02	*51:01	*07:04	*14:02	SBT, P-SSP, P-SSO
792	Gandhi, Manis	*02:01		*44:02	*51:01	*07:04	*14:02	SSO, SSP
2344	Hurley/Hartz	*02:01:01G	*02:01:01G	*44:02:01G	*51:01:01G	*07:04:01G	*14:02:01G	SBT, SSOP
794	Jaatinen, Tai	*02:01		*44:02	*51:01	*07:04/11	*14:02	SBT, SSO, SSP
2847	Kihara, Masaaki	*02		*44	*51	*07	*14	RVSSO
4337	Kim, Tai-Gyu	*02:01		*44:02	*51:01	*07:04	*14:02	SBT
1694	Kissel&Hess	*02		*44	*51	*07	*14	SSP
168	Klein, Tirza	*02:01		*44:02	*51:01	*07:04	*14:02	P-SSO, SSP
9000	Klein_LR	*02		*44	*51	*07	*14	P-SSO, SSP
278	Lee, Jar-How	*02:01		*44:02	*51:01	*07:04	*14:02	SSP, RVSSOP
274	Lo, Raymundo	*02	*02	*44	*51	*07	*14:13	SSO
8029	Mani, Rama	*02	*02	*44	*51	*07	*14	SSO
8052	Marcos, Cintia Y	*02	*02	*44	*51	*07:04/11/63/142+	*14	P-SSO
54	Pancoska, Ca	*02		*44	*51	*07	*14	RVSSO
3966	Permpikul&Ve	*02	*02	*44	*51	*07	*14	P-SSP
2400	Phelan, Donna	*02:01		*44:02/19N	*51:01	*07:04/11	*14:02	SSO, SBT, SSP
3753	Reed, Elaine	*02:01	*02:01	*44:02/12/19N/34+	*51:01/08/46/78+	*07:04/11/181	*14:02/13	SBT, SSO
3519	Renac, Virginie	*02:01		*44:02	*51:01	*07	*14	SBT, P-SSP
3519	Renac, Virginie_LR	*02		*44	*51	*07	*14	P-SSP
4251	Schiller, J	*02:01	*02:01	*44:02:01G	*51:01	*07:04:01G	*14:02	P-RVSSO, SBT
8068	Shanmugam, He	*02		*44	*51	*07	*14	P-SSP
1108	Sutherland, L	*02	*02	*44	*51	*07	*14	SSOP
5462	Turner, E.V.	*02:01/01L		*44:02/02S	*51:01	*07	*14	SSP, SSO, SBT

Table 5: Individual laboratory results for B-cell #502-Class II

Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD
5488	Adams, Sharon	*07:01:01	*11:19:01	*02	*01	*02:01	*05:05	*02:02:01	*03:01:01		*02:01:02	*04:01:01	SSO, SBT, SSP
4691	Ajlan, Abdula	*07:01	*11:19					*02:02	*03:01/27+				SSO, SBT
8038	Cao, Kai	*07:01:01	*11:19:01	*02:02/28+	*01:01/03/06	*02:01	*05:05/09+	*02:02:01	*03:01:01	*01:03	*02:01/*141:01	*04:01	SSO, SSP, SBT
774	Cecka, J. Mich	*07:01/18+	*11:19	*02:02/228+	*01:03	*02:01	*05:05	*02:02/06+	*03:01/21+				SSO, SSP
8070	Chang, Uckjin	*07	*11										P-SSP
9916	Charlton, Ron	*07:01:01	*11:19:01	*02:02	*01:03			*02:02/11+	*03:01/75+				SSP, SBT
9916	Charlton_LR	NT											SBT, SSP
4492	Charron, D.	*07:01/25+	*11:19	*02:02	*01:03	*02:01	*05:05/09+	*02:02/12	*03:01/27+	*01:03	*02:01/*141:01/+	*04:01/*149:01	P-SSO, SSP
8021	Clark, Brenda	*07:01	*11:19	*02:02+	*01			*02:02	*03:01		*02:01	*04:01	P-SSP, RVSSO
3632	Colombe, Beth	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01				SSOP, SSP
5130	Costeas, Paul	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01				SSO, SSP
779	Daniel, Claud	*07	*11:19	*02	*01	*02:01	*05:05	*02:02/12	*03:01	*01:03	*02:01	*04:01	P-SSP, SSO
5219	Daniel, Dolly	*07	*11					*02	*03				P-SSOP
5891	Du, Keming	*07:01	*11:19					*02:02/03	*03:01/04				P-SBT
3766	Dunn, Paul	*07	*11	*+	*+	*02:01	*05	*02	*03	*01	*02:01	*04:01	RT-PCR, SSO
5214	Eckels/CPMC	*07	*11:19	*02	*01	*02:01	*05	*02	*03 (DQ7)	*01:03	*02:01P	*04:01	SSOP
3135	Enczmann, J	*07:01	*11:19	*02:02	*01:03			*02:02	*03:01		*02:01	*04:01	SBT, P-SSP, P-SSO
762	Fischer, Got	*07:01	*11:19	*02:02/28	*01:03	*02:01	*05:05	*02:02	*03:01/19		*02:01	*04:01	SSO, SBT
4079	Fort, Marylis	*07	*11					*02	*03		*02:01	*04:01	SSP
792	Gandhi, Manis	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01		*02:01	*04:01	SSO, SSP
8043	Gideoni, Osna	*07:01	*11:19			*02:01	*05:05	*02:02	*03:01	*01:03	*02:01	*04:01	SSP
9002	Gideoni_LR	*07	*11					*02	*03				SSO
910	Hahn, Amy B.	*07	*11	*+	*+	*02:01	*05:05	*02	*03				SSP
2344	Hurley/Hartz	*07:01:01G	*11:19:01			*02:01	*05:05:01G	*02:02	*03:01:01G	*01:03:01G	*02:01:02	*04:01:01G	SBT, SSOP
771	Israel, Shosh	*07:01	*11:19					*02:02	*03:01				SSP
9003	Israel_LR	*07	*11					*02	*03				SSO
794	Jaatinen, Tai	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05/09+	*02:02	*03:01	*01:03	*02:01/*141:01	*04:01	SBT, SSO, SSP
8086	Jie, Pan	*07:01	*11:19			*02:01	*05:05	*02:02	*03:01		*02:01	*04:01	
2847	Kihara, Masaaki	*07	*11										rSSO
4337	Kim, Tai-Gyu	*07:01	*11:19					*02:02	*03:01		*02:01	*04:01	SBT
1694	Kissel&Hess	*07	*11	*+	*+			*02:02	*03:01				SSP
168	Klein, Tirza	*07:01	*11:19					*02:02	*03:01				P-SSO, SSP
9000	Klein_LR	*07	*11					*02	*03				P-SSO, SSP
87	Land, Geoffre	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01		*02:01	*04:01	SBT, SSO, SSP
725	Lardy, N.M.	*07	*11	*+	*+	*02	*05	*02	*03				SSO, SSP
278	Lee, Jar-How	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01	*01:03	*02:01	*04:01	SSP, RVSSOP
6649	Lim, Young Ae	*07	*11	*+	*+								SSP
274	Lo, Raymundo	*07	*11:19			*02:01	*05	*03	*03	*01:03	*02:01	*04:01	SSO
759	Lopez-Cepero	*07:01/03+	*11:19	*02:02/27+	*01:01/03/06	*02:01	*05:05/09	*02:02	*03:01/27+	*01:03	*02:01P	*04:01P	RVSSO
8029	Mani, Rama	*07	*11					*02	*03				SSO
8052	Marcos, Cintia Y	*07	*11:19			*02:01	*05:05/09+	*02:02/10+	*03				P-SSO
206	McAlack-Hana	*07	*11	*02	*01	*02	*05	*02	*03 (DQ7)				RVSSOP

Table 5: Individual laboratory results for B-cell #502-Class II

Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD
8042	Muncher,Lior	*07:01	*11:19					*02:02	*03:01				SSO,SSP
9001	Muncher_LR	*07	*11					*02	*03				SSO,SSP
54	Pancoska,Ca	*07	*11	*02	*01	*02:01	*05	*02	*03	*01:03	*02	*04	RVSSO
3966	Permpikul&Ve	*07:01	*11:19	*02:02	*01:03			*02:02	*03:01				P-SSP
2400	Phelan,Donna	*07:01	*11:19	*02	*01	*02:01	*05:05/09+	*02:02	*03:01		*02:01	*04:01	SSO,SBT,SSP
8001	Rao,Prakash	*07:01	*11:19	*02:02	*01:03	*02	*05	*02:02	*03:01		*02:01	*04:01	RVSSO,SSP
3753	Reed,Elaine	*07:01	*11:19	*02:02/27+	*01:01/03/06	*02:01	*05:05/09+	*02:02	*03:01				SBT,SSO
3519	Renac,Virginie	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01		*02:01	*04:01	SBT,P-SSP
3519	Renac,Virginie_LR	*07	*11					*02	*03				P-SSP
1160	Rosen-Bronson	*07	*11:19	*02	*01			*02	*03				SSO
4251	Schiller,J	*07:01	*11:19	*02:02/27+	*01:01/03/06	*02	*05	*02:02	*03:01	*01	*02:01:02G	*04:01:01G	P-RVSSO,SBT
8068	Shanmugam,He	*07	*11	*+	*+			*02	*03				P-SSP
1108	Sutherland,L	*07	*11	*02	*01	*03	*05	*02	*03				SSOP
747	Tiercy,Jean-	*07:01:01	*11:19:01	*02:02	*01:03	*02:01	*05:05/09+	*02:02	*03:01		*02:01:02	*04:01:01	SSO,SSP,SBT
5451	Tilanus,Marc	*07:01:01	*11:19:01	*+	*+			*02	*03				SBT,SSP
5462	Turner,E.V.	*07:01	*11:19	*02:02/28+	*01:03			*02:02	*03:01		*02:01/*141:01	*04:01	SSP,SSO,SBT
5642	Varnavidou-N	*07:01/18+	*11:19	*+	*+			*02:02/06+	*03:01/21+				P-SSP
797	Yabe,Hiromasa	*07:01	*11:19			*02:01	*05:05/09	*02:02	*03:01/27+				SSO
3511	Zeevi,Adrian	*07:01	*11:19	*02:02	*01:03	*02:01	*05:05	*02:02	*03:01		*02:01	*04:01	RVSSOP,SSP

CTR	DIRNAME	DR7	DR11	DR52	DR53			DQ2	DQ7	OTH1	OTH2
4492	Charron,D.	+	+	+	+			+	+		
910	Hahn,Amy B.	+	+	+	+			+	+		
4908	Kvam,Vonnett	+	+	+	+			+	DQ3		
54	Pancoska,Car	+	+	+	+			+	+		
793	Rubocki,Rona	+	+	+	+			+	+		

Table 6: Individual laboratory results for B-cell #502-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*02:01	*24:02	*07	*13	*06	*07	SSO, SBT, SSP
4691	Ajjan, Abdula	*02:01	*24:02	*07	*13	*06:11	*07:02	SSO, SBT
8038	Cao, Kai	*02:01:01	*24:02	*07:02/61/161N	*13:02:01	*06:02/83	*07:02/50	SSO, SSP, SBT
774	Cecka, J. Mich	*02	*24	*02:02/26/28+	*13	*06	*07	SSO, SSP
9916	Charlton, Ron	*02:01:01	*24:02	*07:02:01	*13:02:01	*06:02:01:01	*07:02:01	SSP, SBT
9916	Charlton_LR	NT						SSP
4492	Charron, D.	*02:01/01L/97/266+	*24:02/135/144/154+	*07:02/185/189/190	*13:02/38/65/68/70	*06:02/97/100	*07:02/159/195+	P-SSO, SSP
8021	Clark, Brenda	*02:01+	*24:02+	*07:02+	*13:02+	*06:02+	*07:02+	P-SSP, RVSSO
5130	Costeas, Paul	*02:01	*24:02/135	*07:02	*13:02	*06:02	*07:02/99/183	SSO, SSP
5219	Daniel, Dolly	*02	*24	*07	*13	*06	*07	P-SSOP
5891	Du, Keming	*02:01/04/12/36/37+	*24:02/52/13/03/33+	*07:02/26/61/86+	*13:02/18/14/54/09	*06:02/04/11/31+	*07:02/50/138/76+	P-SBT
3766	Dunn, Paul	*02	*24	*07	*13	*06	*07	RT-PCR, SSO
3135	Enczmann, J	*02:01/01L	*24:02	*07:02	*13:02	*06:02	*07:02	SBT, P-SSP, P-SSO
792	Gandhi, Manis	*02:01	*24:02	*07:02	*13:02	*06:02	*07:02	SSO, SSP
2344	Hurley/Hartz	*02:01:01G	*24:02:01G	*07:02:01G	*13:02:01G	*06:02:01G	*07:02:01G	SBT, SSOP
794	Jaatinen, Tai	*02:01	*24:02	*07:02/61/161N	*13:02	*06:02/83	*07:02/50	SBT, SSO, SSP
2847	Kihara, Masaaki	*02	*24	*07	*13	*06	*07	RVSSO
4337	Kim, Tai-Gyu	*02:01	*24:02	*07:02	*13:02	*06:02	*07:02	SBT
1694	Kissel&Hess	*02	*24	*07	*13	*06	*07	SSP
168	Klein, Tirza	*02:01	*24:02	*07:02	*13:02	*06:02	*07:02	P-SSO, SSP
9000	Klein_LR	*02	*24	*07	*13	*06	*07	P-SSO, SSP
278	Lee, Jar-How	*02:01	*24:02	*07:02	*13:02	*06:02	*07:02	SSP, RVSSOP
274	Lo, Raymundo	*02	*24	*07	*13	*06	*07	SSO
8029	Mani, Rama	*02	*24	*07	*13	*06	*07	SSO
8052	Marcos, Cintia Y	*02	*24	*07	*13	*06	*07	P-SSO
54	Pancoska, Ca	*02	*24	*07	*13	*06	*07	RVSSO
3966	Permpikul&Ve	*02	*24	*07	*13	*06	*07	P-SSP
2400	Phelan, Donna	*02:01	*24:02	*07:02/61/161N	*13:02	*06:02/83	*07:02/50	SSO, SBT, SSP
3753	Reed, Elaine	*02:01/04/12/36/37+	*24:02/03/13/14/28+	*07:02/26/61/86+	*13:02/09/14/18/54	*06:02/04/11/31+	*07:02/27/50/76+	SBT, SSO
3519	Renac, Virginie	*02:01	*24:02	*07:02	*13:02	*06:02	*07:02	SBT, P-SSP
3519	Renac, Virginie_LR	*02	*24	*07	*13	*06	*07	P-SSP
4251	Schiller, J	*02:01	*24:02	*07:02:01G	*13:02	*06:02:01G	*07:02:01G	P-RVSSO, SBT
8068	Shanmugam, He	*02	*24	*07	*13	*06	*07	P-SSP
1108	Sutherland, L	*02	*24	*07	*13	*06	*07	SSOP
5462	Turner, E.V.	*02:01/01L	*24:02	*07:02/61/161N	*13:02	*06:02	*07:02	SSP, SSO, SBT

Table 7: Summary of the 252nd B-cell Line Exchange

Ter-503

DNA Typing - class II		<u>61 LABS - DRB1</u>		<u>40 LABS - DRB3</u>		<u>33 LABS - DQA1</u>		<u>58 LABS - DQB1</u>		<u>13 LABS - DPA1</u>		<u>29 LABS - DPB1</u>						
			%(n)				%(n)		%(n)		%(n)		%(n)					
	DRB1*03:01:01	3	(2)	DRB3*02:02	38	(15)	DQA1*01:02:01G	3	(1)	DQB1*02:01:01	9	(5)	DPA1*01:03	86	(12)	DPB1*02:02	100	(30)
	DRB1*03:01:01G	2	(1)	DRB3*02:02+	20	(8)	DQA1*01:02	43	(14)	DQB1*02:01	41	(24)	DPA1*01	14	(2)			
	DRB1*03:01	38	(23)	DRB3*02	20	(8)	DQA1*01:02+	27	(9)	DQB1*02:01+	16	(9)						
	DRB1*03:01+	18	(11)	DRB3*+	22	(9)	DQA1*01	27	(9)	DQB1*02	34	(20)						
	DRB1*03(DR17)	10	(6)															
	DRB1*03	29	(18)															
	DRB1*13:29	65	(39)	<u>40 LABS - DRB3</u>			DQA1*05:01	79	(26)	DQB1*06:04:01	5	(3)				DPB1*03:01:01	3	(1)
	DRB1*13:29+	3	(2)	DRB3*03:01	68	(27)	DQA1*05	21	(7)	DQB1*06:04:01G	2	(1)				DPB1*03:01:01G	7	(2)
	DRB1*13	32	(19)	DRB3*03	10	(4)			DQB1*06:04	38	(22)				DPB1*03:01P	3	(1)	
				DRB3*+	22	(9)			DQB1*06:04+	17	(10)				DPB1*03:01	53	(16)	
									DQB1*06	38	(22)				DPB1*03:01/*104:01	20	(6)	
															DPB1*03:01/+	13	(4)	
Serology - class II		<u>5 LABS - DR</u>						<u>5 LABS - DQ</u>										
			%(n)						%(n)									
	DR17	60	(3)	DR52	100	(5)			DQ6	20	(1)							
	DR3	40	(2)						DQ1	80	(4)							
	DR13	100	(5)						DQ2	100	(5)							
DNA Typing - class I		<u>35 LABS - HLA-A</u>		<u>35 LABS - HLA-B</u>		<u>35 LABS - HLA-C</u>												
			%(n)		%(n)		%(n)											
	A*26:01:01	6	(2)	B*18:01:01:01	3	(1)	C*03:04:01G	3	(1)									
	A*26:01:01G	3	(1)	B*18:01:01	3	(1)	C*03:04	34	(12)									
	A*26:01	31	(11)	B*18:01:01G	6	(2)	C*03:04+	14	(5)									
	A*26:01+	14	(5)	B*18:01	26	(9)	C*03(Cw10)	6	(2)									
	A*26	43	(15)	B*18:01+	14	(5)	C*03	43	(15)									
	A*03	3	(1)	B*18	48	(17)												
	A*30:02:01	6	(2)	B*40:01:02	3	(1)	C*05:01:01G	3	(1)									
	A*30:02:01G	3	(1)	B*40:01:01G	3	(1)	C*05:01	34	(12)									
	A*30:02	31	(11)	B*40:01	37	(13)	C*08:35	3	(1)									
	A*30:02+	14	(5)	B*40:01+	11	(4)	C*05:01+	14	(5)									
	A*30	46	(16)	B*40(B60)	6	(2)	C*05	43	(15)									
				B*40	40	(14)	C*08	3	(1)									

Table 9: Individual laboratory results for B-cell #503-Class II

Center	Investigator	DRB1		DRB3		DQA1		DQB1		DPA1		DPB1		METHOD
5488	Adams,Sharon	*03:01:01	*13:29	*02	*03:01	*01:02/11	*05:01	*02:01:01	*06:04:01			*02:02	*03:01:01	SSO,SBT,SSP
4691	Ajlan,Abdula	*03:01/05	*13:29/20					*02	*06					SSO,SBT
8038	Cao,Kai	*03:01	*13:29	*02:02/28/29N	*03:01	*01:02/08/09+	*05:01	*02:01:01	*06:04:01	*01:03		*02:02	*03:01/*104:01	SSO,SBT
774	Cecka,J.Mich	*03:01/56/61+	*13:29	*02:02/26/28+	*03:01	*01:02	*05:01	*02:01/07/08+	*06:04/34+	*01:03		*02:02	*03:01	SSP
8070	Chang,Uckjin	*03												P-SSP
9916	Charlton,Ron	*03:01:01	*13:29	*02:02	*03:01			*02:01/07/08+	*06:04/58+					SSP,SBT
9916	Charlton_LR	*03	*13	*+				*02	*06					SSP
4492	Charron,D.	*03:01/83/86	*13:29	*02:02	*03:01	*01:02/08/09+	*05:01	*02:01/27	*06:04/86	*01:03		*02:02	*03:01/*104:01	P-SSO,SSP
8021	Clark,Brenda	*03:01	*13:29	*02:02/27-29N	*03:01			*02:01	*06:04			*02:02	*03:01	P-SSP,RVSSO
3632	Colombe,Beth	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04					SSOP,SSP
5130	Costeas,Paul	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04					SSO,SSP
779	Daniel,Claud	*03 (DR17)	*13	*02	*03:01	*01:02	*05:01	*02	*06	*01:03		*02:02	*03:01	P-SSP,SSO
5219	Daniel,Dolly	*03	*13					*02	*06					P-SSOP,P-SSP
5891	Du,Keming	*03:01/50/68N+	*13:29					*02:01/31	*06:04/89					P-SBT
3766	Dunn,Paul	*03	*13:29/140	*+		*01	*05	*02	*06	*01		*02:02	*03:01	RT-PCR,SSP
5214	Eckels/CPMC	*03 (DR17)	*13:29	*02	*03:01	*01	*05:01	*02	*06	*01:03		*02:02	*03:01	SSOP
3135	Enczmann,J	*03:01	*13:29	*02:02	*03:01			*02:01	*06:04			*02:02	*03:01	SBT,P-SSP,P-SSO
762	Fischer,Got	*03:01	*13:29	*02:02/12/28+	*03:01	*01:02	*05:01	*02:01	*06:04/34+			*02:02	*03:01/*104:01	SSO,SBT
4079	Fort,Maryliss	*03:01/50/68N+	*13:29			*01:02/08/09+	*05:01	*02:01/27	*06:04/34+			*02:02	*03:01/*124:01	SSP,SSO
792	Gandhi,Manis	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04			*02:02	*03:01	SSO,SSP
8043	Gideoni,Osna	*03:01	*13:29			*01:02	*05:01	*02:01	*06:04	*01:03		*02:02	*03:01	SSP
9002	Gideoni_LR	*03	*13					*02	*06					SSO
910	Hahn,Amy B.	*03	*13	*+		*01:02	*05:01	*02	*06					SSP
2344	Hurley/Hartz	*03:01:01G	*13:29			*01:02	*05:01	*02:01:01	*06:04:01G	*01:03		*02:02	*03:01:01G	SBT,SSOP
771	Israel,Shosh	*03:01	*13:29					*02:01	*06:04					SSP
9003	Israel_LR	*03	*13					*02	*06					
794	Jaatinen,Tai	*03:01/83	*13:29	*02:02	*03:01	*01:02/08/09+	*05:01	*02:01	*06:04	*01:03		*02:02	*03:01/*104:01	SBT,SSO,SSP
2847	Kihara,Masaaki	*03	*13											RVSSO
4337	Kim,Tai-Gyu	*03:01	*13:29					*02:01	*06:04			*02:02	*03:01	SBT,SSP
1694	Kissel&Hess	*03	*13	*+				*02:01	*06:04					SSP
168	Klein,Tirza	*03:01	*13:29					*02:01	*06:04					P-SSO,SSP
9000	Klein_LR	*03	*13					*02	*06					P-SSO,SSP
87	Land,Geoffre	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04			*02:02	*03:01	SBT,SSO,SSP
725	Lardy,N.M.	*03	*13	*+		*01	*05	*02	*06					SSO,SSP
278	Lee,Jar-How	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04	*01:03		*02:02	*03:01	SSP,RVSSOP
6649	Lim,Young Ae	*03 (DR17)	*13	*+	*+									SSP
274	Lo,Raymundo	*03	*13			*01:02	*05:01	*02:01	*06	*01:03	*01:03	*02:02	*03:01	SSO
731	Loewenthal,R	*03:01	*13:29					*02:01:01	*06:04					SBT,SSO
759	Lopez-Cepero	*03:01/04/13+	*13:29	*02:02/27/28	*03:01	*01:02/08/09	*05:01	*02:01	*06:04/34+	*01:03		*02:02	*03:01P	RVSSO
8029	Mani,Rama	*03	*13					*02	*06					SSO
8052	Marcos,Cintia Y	*03	*13:29			*01:02/08/09+	*05:01	*02:01/07/08+	*06					P-SSO
206	McAlack-Hana	*03 (DR17)	*13	*02	*03	*01	*05	*02	*06					RVSSOP
8042	Muncher,Lior	*03:01	*13:29					*02:01	*06:04					SSO,SSP
9001	Muncher_LR	*03	*13					*02	*06					SSO,SSP
54	Pancoska,Ca	*03 (DR17)	*13:29	*02	*03:01	*01	*05:01	*02	*06	*01:03	*01:03	*02:02	*03:01	RVSSO
3966	Perpikul&Ve	*03:01	*13:29	*02:02	*03:01			*02:01	*06:04					P-SSP

Table 9: Individual laboratory results for B-cell #503-Class II

Center	Investigator	DRB1		DRB3		DQA1		DQB1		DPA1		DPB1		METHOD
2400	Phelan, Donna	*03:01	*13:29	*02	*03	*01:02:01G	*05:01	*02:01	*06:04			*02:02	*03:01/*104:01	SSO, SBT, SSP
8001	Rao, Prakash	*03:01	*13:29	*02:02	*03:01	*01	*05	*02:01	*06:04			*02:02	*03:01/*104:01	RVSSO, SSP
3753	Reed, Elaine	*03:01	*13:29	*02:02/27/28+	*03:01	*01:02/08/09+	*05:01	*02:01/31	*06:04/89					SBT, SSO
3519	Renac, Virginie	*03:01/83	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04			*02:02	*03:01/*104:01*	SBT, P-SSP
3519	Renac, Virginie_LR	*03	*13					*02	*06			*02:02	*03:01/*124:01	P-SSP
1160	Rosen-Bronson	*03:01/83/86	*13:29	*02:02	*03:01			*02:01/31	*06:04/89					SSO, SSP, SBT
793	Rubocki, Rona	*03 (DR17)	*13	*02	*03	*01	*05	*02	*06			*02:02	*03:01	SSP
4251	Schiller, J	*03:01	*13:29	*02:02/27/28+	*03:01	*01	*05	*02:01	*06:04	*01	*01	*02:02	*03:01:01G	P-RVSSO, SBT
8068	Shanmugam, He	*03	*13	+				*02	*06					P-SSP
1108	Sutherland, L	*03	*13	*02	*03	*01	*05	*02	*06					SSOP
747	Tiercy, Jean-	*03:01	*13:29	*02:02	*03:01	*01:02/08/09+	*05:01	*02:01:01	*06:04:01			*02:02	*03:01/*124:01	SSO, SSP, SBT
5451	Tilanus, Marc	*03:01	*13:29	+				*02	*06					SBT, SSP
5462	Turner, E.V.	*03:01/68N/83	*13:29	*02:02/28/29N	*03:01			*02:01	*06:04			*02:02	*03:01	SSP, SSO, SBT
5642	Varnavidou-N	*03:01/32/39+	*13:29	+				*02:01/07/08+	*06:04/34+					P-SSP
3511	Zeevi, Adrian	*03:01	*13:29	*02:02	*03:01	*01:02	*05:01	*02:01	*06:04			*02:02	*03:01	RVSSOP, SSP

CTR	DIRNAME	DR17	DR13	DR52				DQ2	DQ1	OTH1	OTH2
4492	Charron, D.	DR3	+	+				+	+		
910	Hahn, Amy B.	+	+	+				+	+		
4908	Kvam, Vonnett	+	+	+				+	+		
54	Pancoska, Car	+	+	+				+	DQ6		
793	Rubocki, Rona	DR3	+	+				+	+		

Table 10: Individual laboratory results for B-cell #503-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*26:01:01/05	*30:02:01/57	*18	*40	*03	*05	SSO, SBT, SSP
4691	Ajlan, Abdula	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SSO, SBT
8038	Cao, Kai	*26:01:01	*30:02:01	*18:01:01	*40:01	*03:04	*05:01	SSO, SBT
774	Cecka, J. Mich	*26	*30	*18	*40	*03	*05	SSP
9916	Charlton, Ron	*26:01:01	*30:02:01	*18:01:01:01	*40:01:02	*03:04	*05:01	SSP, SBT
9916	Charlton_LR	*26	*30	*18	*40	*03	*05	SSP
4492	Charron, D.	*26:01/77/80/82/85	*30:02/66/70N	*18:01/53/73/87+	*40:01/88/133+	*03:04/100/105+	*05:01/90/94	P-SSO, SSP
8021	Clark, Brenda	*26:01+	*30:02+	*18:01+	*40:01+	*03:04+	*05:01+	P-SSP, RVSSO
3632	Colombe, Beth	*26	*30	*18	*40	*03	*05	SSOP, SSP
5130	Costeas, Paul	*26:01	*30:02	*18:01	*40:01	*03:04/63	*05:01/10	SSO, SSP
5219	Daniel, Dolly	*26	*30	*18	*40	*03	*08	P-SSOP
5891	Du, Keming	*26:01/05	*30:02/57	*18:01/11/12/17N+	*40:01/113/25/52+	*03:04/10/41	*05:01/20/86	P-SBT
3766	Dunn, Paul	*26	*30	*18	*40	*03	*05	RT-PCR, SSP
5214	Eckels/CPMC	*26	*30	*18	*40(B60)	*03(Cw10)	*05	SSO, SSP
3135	Enczmann, J	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SBT, P-SSP, P-SSO
792	Gandhi, Manis	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SSO, SSP
2344	Hurley/Hartz	*26:01:01G	*30:02:01G	*18:01:01G	*40:01:01G	*03:04:01G	*05:01:01G	SBT, SSOP
794	Jaatinen, Tai	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SBT, SSO, SSP
2847	Kihara, Masaaki	*26	*30	*18	*40	*03	*05	RVSSO
4337	Kim, Tai-Gyu	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SBT, SSP
1694	Kissel&Hess	*26	*30	*18	*40	*03	*05	SSP
278	Lee, Jar-How	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SSP, RVSSOP
274	Lo, Raymundo	*03	*30	*18	*40	*03	*08:35	SSO
8029	Mani, Rama	*26	*30	*18	*40	*03	*05	SSO
8052	Marcos, Cintia Y	*26	*30	*18	*40	*03	*05	P-SSO
54	Pancoska, Ca	*26	*30	*18	*40(B60)	*03(Cw10)	*05	RVSSO
3966	Permpikul&Ve	*26	*30	*18	*40:01	*03	*05	P-SSP
2400	Phelan, Donna	*26:01	*30:02	*18:01/17N	*40:01	*03:04	*05:01	SSO, SBT, SSP
3753	Reed, Elaine	*26:01/05	*30:02/57	*18:01/11/12/17+	*40:01/25/52/74+	*03:04/09/28/35+	*05:01/05/10/11/27+	SBT, SSO
3519	Renac, Virginie	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SBT, P-SSP
3519	Renac, Virginie_LR	*26	*30	*18	*40	*03	*05	P-SSP
4251	Schiller, J	*26:01	*30:02	*18:01:01G	*40:01	*03:04	*05:01	P-RVSSO, SBT
8068	Shanmugam, He	*26	*30	*18	*40	*03	*05	P-SSP
1108	Sutherland, L	*26	*30	*18	*40	*03	*05	SSOP
5462	Turner, E.V.	*26:01	*30:02	*18:01	*40:01	*03:04	*05:01	SSP, SSO, SBT

Table 11: Individual laboratory results for B-cell #504-Class II

Center	Investigator	DRB1		DRB3	DRB5	DQA1		DQB1		DPA1		DPB1		METHOD
5488	Adams,Sharon	*13:01:01	*15:02:01	*02	*01	*01:03/10		*06:01	*06:08:01			*09:01:01	*105:01	SSO,SBT,SSP
4691	Ajlan,Abdula	*13:01/117	*15:02					*06	*06					SSO,SBT
8038	Cao,Kai	*13:01/117	*15:02:01	*02:02/28+	*01:02	*01:03/10		*06:01	*06:08	*02:01	*03:01	*09:01:01	*105:01	SSO,SSP,SBT
774	Cecka,J.Mich	*13:01/138+	*15:02/44+	*02:02/26+	*01:02	*01:03		*06:01/54N+	*06:08	*02:01	*03:01	*09:01	*105:01	SSP
8070	Chang, Uckjin	*13	*15											P-SSP
9916	Charlton,Ron	*13:01:01	*15:02:01	*02:02	*01:02			*06:01/98+	*06:08:01					SSP,SBT
9916	Charlton_LR	*13	*15	*+	*+			*06	*06					SSP
4492	Charron,D.	*13:01/105+	*15:02/80N	*02:02	*01:02	*01:03/10		*06:01/54N+	*06:08	*02:01	*03:01	*09:01	*105:01	P-SSO,SSP
8021	Clark,Brenda	*13:01	*15:02	*02:02	*01:02			*06:01	*06:08			*09:01	*105:01	P-SSP,RVSSO
3632	Colombe,Beth	*13:01	*15:02	*02:02	*01:02	*01:03		*06:01	*06:08					SSOP,SSP
5130	Costeas,Paul	*13:01/113N	*15:02	*02:02	*01:02	*01:03	*01:03	*06:01	*06:08					SSO,SSP
779	Daniel,Claud	*13	*15	*02	*01	*01:03		*06	*06:08	*02:01	*03:01	*09:01	*105:01	P-SSP,SSO
5219	Daniel,Dolly	*13	*15					*06	*06					P-SSOP
5891	Du,Keming	*13:01/105+	*15:02/19					*06:01/108	*06:08					P-SBT
3766	Dunn,Paul	*13	*15	*02	*01	*01		*06	*06	*02	*03	*09:01	*04:02	RT-PCR,SSO,SSP
5214	Eckels/CPMC	*13	*15	*02	*01	*01	*01	*06	*06:08	*02:01	*03:01	*09:01	*105:01	SSOP
3135	Enczmann,J	*13:01	*15:02	*02:02	*01:02			*06:01	*06:08			*09:01	*105:01	SBT,P-SSP,P-SSO
762	Fischer,Got	*13:01/117	*15:02	*02:02/12+	*01:02	*01:03		*06:01/105+	*06:08			*09:01	*105:01	SSO,SBT,SSP
4079	Fort,Maryliss	*13:01/105+	*15:02/80N			*01:03/10		*06:01	*06:08			*09:01	*105:01	SSP,SSO
792	Gandhi,Manis	*13:01	*15:02	*02:02	*01:02	*01:03/10		*06:01	*06:08			*09:01	*105:01	SSO,SSP
8043	Gideoni,Osna	*13:01	*15:02			*01:03		*06:01	*06:08					SSP
9002	Gideoni_LR	*13	*15					*06						SSO,SSP
910	Hahn,Amy B.	*13	*15	*+	*+	*01:03		*06						SSP
2344	Hurley/Hartz	*13:01:01G	*15:02:01			*01:03		*06:01:01G	*06:08:01	*02:01:01	*03:01	*09:01	*04:02:01G	SBT,SSOP
771	Israel,Shosh	*13:01	*15:02					*06:01	*06:08					SSP
9003	Israel_LR	*13	*15					*06						SSO
794	Jaatinen,Tai	*13:01/105+	*15:02	*02:02	*01:02	*01:03/10		*06:01	*06:08	*02:01	*03:01	*09:01	*105:01	SBT,SSO,SSP
2847	Kihara,Masaaki	*13	*15											rSSO
4337	Kim,Tai-Gyu	*13:01	*15:02					*06:01	*06:08			*09:01	*04:02	SBT,SSP
1694	Kissel&Hess	*13	*15	*+	*+			*06:01	*06:08					SSP
168	Klein,Tirza	*13:01	*15:02					*06:01	*06:08					P-SSO,SSP
9000	Klein_LR	*13	*15					*06	*06					P-SSO,SSP
87	Land,Geoffre	*13:01	*15:02	*02:02	*01:02	*01:03	*01:03	*06:01	*06:08			*09:01	*105:01	SBT,SSO,SSP
725	Lardy,N.M.	*13	*15	*+	*+	*01		*06						SSO,SSP
278	Lee,Jar-How	*13:01	*15:02	*02:02	*01:02	*01:03		*06:01	*06:08	*02:01	*03:01	*09:01	*105:01	SSP,RVSSOP
6649	Lim,Young Ae	*13	*15	*+	*+									SSP
274	Lo,Raymundo	*13	*15			*01:03	*01:03	*06	*06:08	*02:01	*03:01	*09:01	*105:01	SSO
731	Loewenthal,R	*13:01	*15:02					*06:01	*06:08:01					SBT,SSO
759	Lopez-Cepero	*13:01/28+	*15:02/08+	*02:02/27+	*01:02/08N	*01:03		*06:01/43	*06:08	*02:01	*03:01	*09:01	*04:02P	RVSSO
8029	Mani,Rama	*13	*15					*06	*06					SSO
8052	Marcos,Cintia Y	*13	*15			*01:03/10	*01:03/10	*06:01/43+	*06:08					P-SSO
206	McAlack-Hana	*13	*15	*02	*01	*01		*06	*06					RVSSOP
8042	Muncher,Lior	*13:01	*15:02					*06:01	*06:08					SSO,SSP
9001	Muncher_LR	*13	*15					*06						SSO,SSP
54	Pancoska,Ca	*13	*15	*02	*01	*01	*01	*06	*06:08	*02:01	*03:01	*09:01	*105:01	RVSSO
3966	Permpikul&Ve	*13:01	*15:02	*02:02	*01:02			*06:01	*06:08					P-SSP

Table 11: Individual laboratory results for B-cell #504-Class II

Center	Investigator	DRB1		DRB3	DRB5	DQA1		DQB1		DPA1		DPB1		METHOD
2400	Phelan, Donna	*13:01	*15:02	*02	*01:02	*01:03/10		*06:01	*06:08			*09:01	*105:01	SSO, SBT, SSP
8001	Rao, Prakash	*13:01	*15:02	*02:02	*01:02	*01		*06:01	*06:08			*09:01	*105:01	RVSSO, SSP
3753	Reed, Elaine	*13:01	*15:02	*02:02/27+	*01:02/08N	*01:03/10	*01:03/10	*06:01/108	*06:08					SBT, SSO
3519	Renac, Virginie	*13:01/105+	*15:02	*02:02	*01:02	*01:03		*06:01	*06:08			*09:01	*105:01	SBT, P-SSP
3519	Renac, Virginie_LR	*13	*15					*06				*09:01	*105:01	SSP
1160	Rosen-Bronson	*13:01/105+	*15:02	*02:02	*01:02			*06:01	*06:08					SSO, SSP, SBT
793	Rubocki, Rona	*13	*15	*02	*+	*01		*06				*09:01	*105:01	SSP
4251	Schiller, J	*13:01	*15:02	*02:02/27+	*01:02	*01	*01	*06:01	*06:08	*02	*03	*09:01	*04:02:01G	P-RVSSO, SBT
8068	Shanmugam, He	*13	*15	*+	*+			*06						P-SSP
1108	Sutherland, L	*13	*15	*02	*01	*01	*01	*06	*06					SSOP
747	Tiercy, Jean-	*13:01:01	*15:02:01	*02:02	*01:02	*01:03/10		*06:01	*06:08:01			*09:01:01	*105:01	SSO, SSP, SBT
5451	Tilanus, Marc	*13:01:01	*15:02:01	*+	*+			*06						SBT, SSP
5462	Turner, E.V.	*13:01/105+	*15:02	*02:02/28+	*01:02			*06:01	*06:08			*09:01	*105:01	SSP, SSO, SBT
5642	Varnavidou-N	*13:01/91+	*15:02/39+	*+	*+			*06:01/54N+	*06:08					P-SSP
3511	Zeevi, Adrian	*13:01	*15:02	*02:02	*01:02	*01:03		*06:01	*06:08			*09:01	*105:01	RVSSOP, SSP

CTR	DIRNAME	DR13	DR15	DR51	DR52			DQ1		OTH1	OTH2
4492	Charron, D.	+	+	+	+			+			
910	Hahn, Amy B.	+	+	+	+			+			
4908	Kvam, Vonnett	+	+	+	+			+			
54	Pancoska, Car	+	+	+	+			DQ6			
793	Rubocki, Rona	+	+	+	+			+			

Table 12: Individual laboratory results for B-cell #504-Class I

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams,Sharon	*24:02	*68:02:01	*47:03	*52:01:01/07	*07	*12	SSO,SBT,SSP
4691	Ajlan,Abdula	*24:02	*68:02	*47:03	*52:01/07	*07:01/06/18	*12:02	SSO,SBT
8038	Cao,Kai	*24:02	*68:02:01	*47:03	*52:01/07	*07:01/06/18	*12:02:02	SSO,SSP,SBT
774	Cecka,J.Mich	*24	*68	*47	*52	*07	*12	SSP
9916	Charlton,Ron	*24:02	*68:02:01:01	*47:03	*52:01:01/07	*07:18	*12:02:02	SSP,SBT
9916	Charlton_LR	*24	*68	*47	*52	*07	*12	SSP
4492	Charron,D.	*24:02/135/144/154	*68:02	*47:03	*52:01	*07:18	*12:02/96	P-SSO,SSP
8021	Clark,Brenda	*24:02+	*68:02+	*47:03	*52:01+	*07:01+	*12:02+	P-SSP,RVSSO
3632	Colombe,Beth	*24	*68	*47	*52	*07	*12	SSOP,SSP
5130	Costeas,Paul	*24:02	*68:02	*47:03	*52:01	*07:01/18	*12:02	SSO,SSP
5219	Daniel,Dolly	*24	*68	*47	*52	*07	*12	P-SSOP
5891	Du,Keming	*24:02/07/232N	*68:02/31	*47:03	*52:01/07	*07:01/06/18/22+	*12:02/18/08/16	P-SBT
3766	Dunn,Paul	*24	*68	*47:03	*52:01/07/13/23+	*07	*12	RT-PCR,SSO,SSP
5214	Eckels/CPMC	*24	*68	*47:03	*52	*07	*12	SSOP
3135	Enczmann,J	*24:02	*68:02	*47:03	*52:01	*07:01/06/18	*12:02	SBT,P-SSP,P-SSO
792	Gandhi,Manis	*24:02	*68:02	*47:03	*52:01	*07:18	*12:02	SSO,SSP
2344	Hurley/Hartz	*24:02:01G	*68:02:01G	*47:03	*52:01:01G	*07:01:01G	*12:02:01G	SBT,SSOP
794	Jaatinen,Tai	*24:02	*68:02	*47:03	*52:01/07	*07:01/06/18	*12:02	SBT,SSO,SSP
2847	Kihara,Masaaki	*24	*68	*47	*52	*07	*12	RVSSO
4337	Kim,Tai-Gyu	*24:02	*68:02	*47:03	*52:01	*07:01	*12:02	SBT,SSP
1694	Kissel&Hess	*24	*68	*47	*52	*07	*12	SSP
278	Lee,Jar-How	*24:02	*68:02	*47:03	*52:01	*07:18	*12:02	SSP,RVSSOP
274	Lo,Raymundo	*24	*68	*47:03	*52	*07	*12	SSO
8029	Mani,Rama	*24	*68	*47	*52	*07	*12	SSO
8052	Marcos,Cintia Y	*24	*68	*47:02/03	*52:01/07/13/23+	*07	*12	P-SSO
54	Pancoska,Ca	*24	*68	*47	*52	*07	*12	RVSSO
3966	Permpikul&Ve	*24	*68	*47:03	*52	*07	*12	P-SSP
2400	Phelan,Donna	*24:02	*68:02	*47:03	*52:01	*07:01:01G	*12:02	SSO,SBT,SSP
3753	Reed,Elaine	*24:02/07	*68:02/31	*47:03	*52:01/07	*07:01/06/18/22+	*12:02/08/16/18	SBT,SSO
3519	Renac,Virginie	*24:02	*68:02	*47:03	*52:01/07	*07:18	*12:02	SBT,P-SSP
3519	Renac,Virginie_LR	*24	*68	*47	*52	*07	*12	P-SSP
4251	Schiller,J	*24:02	*68:02	*47:03	*52:01:01G	*07:01:01G	*12:02	P-RVSSO,SBT
8068	Shanmugam,He	*24	*68	*47	*52	*07	*12	P-SSP
1108	Sutherland,L	*24	*68	*47	*52	*07	*12	SSOP
5462	Turner,E.V.	*24:02	*68:02	*47:03	*52:01/07	*07:18	*12:02	SSP,SSO,SBT

Cell Exchange #381

The results for Cell Exchange #381 are summarized in Table 13 and Table 14. Molecular typing results for individual laboratories are listed in

Tables 15-18 for each sample and individual serology results for each sample are listed in Table 19.

Cell 1521. The consensus type for this Hispanic sample is A*02:06(A2)-A*68:03(A68)-B*35:12(B35)-B*48:01(B48)-C*04:01(Cw4)-C*08:01(Cw8). The probable haplotypes in this cell are A*68:03-B*35:12-C*04:01 and A*02:06-B*48:01-C*08:01, with respective frequencies of 0.00051 and 0.00505, in Hispanics.

This sample was previously typed as cells 1316 (2007), 1322 (2008), and 1423 (2011), as correctly noted by Askar, Claas, Dunn, Lopez-Cepero, Pancoska, Rees, and Tiercy. In this present retyping, A28 was detected by 93%, with 66% of labs reporting A68. A*68:03 (45%) was reported by DNA. A*02:06 (30%) was reported as the second A-locus type. B35 and B48 were assigned in complete consensus and confirmed as B*35:12 (51%) and B*48:01 (39%). B*35:12:01 and B*48:01:01 were each assigned by 5 labs. C*04:01 (*04:01:01) (32%) and C*08:01 (31%) were the reported C-locus types.

Cell 1522. The consensus type for this Chinese sample is A*24:02(A24)-A*30:01(A30)-B*50:01(B50)-B*55:02(B55)-C*03:03(Cw3)-C*06:02(Cw6). The likely associations in this cell are B*55:02-C*03:03 and B*50:01-C*06:02, with respective frequencies of 0.00288 and 0.00682, in Asians.

B55 (87%) was detected as the B22 split and confirmed as B*55:02 (30%). B*55:02:01 was assigned by 5 labs. B50 (97%) was reported as the second B-locus type. B*50:01 (33%) was reported by DNA, with 5 labs assigning B*50:01:01. A24 (100%) and A30 (97%) were well assigned and confirmed as A*24:02 (30%) and A*30:01 (30%). C*03:03 (34%) and C*06:02 (25%) were the C-locus types.

Cell 1523. The consensus type for this Caucasian sample is A*03:01(A3)-A*69:01(A69)-B*38:01(B38)-B*55:01(B55)-C*03:03(Cw3)-C*12:03. Two strong associations are likely present in this cell, B*55:01-C*03:03 and B*38:01-C*12:03, with respective frequencies of 0.01518 and 0.02122, in Caucasians.

A28 was reported in complete consensus, with 79% of labs assigning A69. A*69:01 (56%) was reported by DNA. A3 was also reported in complete consensus and confirmed as A*03:01 (*03:01:01) by 38%. B38 and B55 were detected by 96% and 93%, respectively, and confirmed as B*38:01 (31%) and B*55:01 (34%). The C-locus types were C*03:03 (35%) and C*12:03 (32%).

Cell 1524. The consensus type for this Asian sample is A*26:01(A26)-A*33:03(A33)-B*40:06(B61)-B*55:02(B55)-C*01:02(Cw1)-C*03:03(Cw3). The probable associations in this cell are B*55:02-C*01:02 and B*40:06-C*03:03, with respective frequencies of 0.00821 and 0.00058, in Asians. The B*40:06-C*03:03 association in this cell was also observed in previous exchange samples, cell 1054, cell 1324 (same as 1356), and cell 906, all from Asian donors.

B40 was detected by 100%, with 75% of labs reporting B61 and 1 lab reporting B40V. B*40:06 was assigned by 41%. B55 (82%) was reported as the B22 split and confirmed as B*55:02 (*55:02:01) (41%). A26 (100%) and A33 (96%) were the reported A-locus types, with DNA assigning A*26:01 (35%) and A*33:03 (35%). A*26:01:01 and A*33:03:01 were each assigned by 4 labs.

Table 13. Summary of the 381st Cell Exchange (Cell #1521-1524)

DNA typing							
Cell 1521		Cell 1522		Cell 1523		Cell 1524	
<u>33 labs</u>	% (n)	<u>33 labs</u>	% (n)	<u>32 labs</u>	% (n)	<u>32 labs</u>	% (n)
A*02:06:01	3 (1)	*24:02:01	3 (1)	A*03:01:01	13(4)	A*26:01:01	13(4)
A*02:06	27(9)	*24:02	27(9)	A*03:01	25(8)	A*26:01	22(7)
A*02:06+	18(6)	*24:02+	9 (3)	A*03:01+	9 (3)	A*26:01+	13(4)
A*02	52(17)	*24	61(20)	A*03	53(17)	A*26	53(17)
A*68:03:01	3 (1)	A*30:01:01	12(4)	A*69:01	56(18)	A*33:03:01	13(4)
A*68:03	42(14)	A*30:01	18(6)	A*69:01+	3 (1)	A*33:03	22(7)
A*68:08	3 (1)	A*30:01+	9 (3)	A*69	41(13)	A*33:03+	13(4)
A*68:03+	6 (2)	A*30	61(20)			A*33	53(17)
A*68	42(14)						
A*36	3 (1)						
<u>33 labs</u>	% (n)	<u>33 labs</u>	% (n)	<u>32 labs</u>	% (n)	<u>32 labs</u>	% (n)
B*35:12:01	15(5)	B*50:01:01	15(5)	B*38:01:01	9 (3)	B*40:06	41(13)
B*35:12	36(12)	B*50:01	18(6)	B*38:01	22(7)	B*40:06+	6 (2)
B*35:10+	3 (1)	B*50:01+	9 (3)	B*38:01+	16(5)	B*40:04+	12(4)
B*35	46(15)	B*50	58(19)	B*38	53(17)	B*40:02+	3 (1)
						B*40(B61)	16(5)
						B*40	22(7)
B*48:01:01	15(5)	B*55:02:01	15(5)	B*55:01:01	9 (3)	B*55:02:01	13(4)
B*48:01	24(8)	B*55:02	15(5)	B*55:01	25(8)	B*55:02	28(9)
B*48:01+	3 (1)	B*55:02+	9 (3)	B*55:01+	9 (3)	B*55:02+	6 (2)
B*48	58(18)	B*55	61(20)	B*55	56(18)	B*55	53(17)
<u>32 labs</u>	% (n)	<u>32 labs</u>	% (n)	<u>31 labs</u>	% (n)	<u>31 labs</u>	% (n)
C*04:01:01	16(5)	C*03:03:01	6 (2)	C*03:03:01	3 (1)	C*01:02	32(10)
C*04:01P	3 (1)	C*03:03:01G	3 (1)	C*03:03:01G	3 (1)	C*01:02+	13(4)
C*04:01	13(4)	C*03:03	25(8)	C*03:03	29(9)	C*01	55(17)
C*04:01+	9(3)	C*03:03+	19(6)	C*03:03+	23(7)		
C*04	59(19)	C*03(Cw9)	13(4)	C*03(Cw9)	13(4)		
		C*03	34(11)	C*03	29(9)		
C*08:01:01	9 (3)	C*06:02:01	6 (2)	C*12:03:01	3 (1)	C*03:03:01G	3 (1)
C*08:01:01G	3 (1)	C*06:02P	3 (1)	C*12:03:01G	3 (1)	C*03:03	32(10)
C*08:01	19(6)	C*06:02	16(5)	C*12:03	26(8)	C*03:03+	23(7)
C*08:01+	9 (3)	C*06:02+	16(5)	C*12:03+	16(5)	C*03(Cw9)	13(4)
C*08	50(19)	C*06	56(18)	C*12	49(15)	C*03	29(9)
		C*12	3 (1)	C*06	3 (1)		

Table 14: Summary of the 381st Cell Exchange (Cell #1521-1524)

(Hispanic) Cell 1521	
(28 Samples Typed)	
A2	100.00%
	[100.0%]
A68	64.30%
A28	28.60%
	[92.9%]
B35	100.00%
B48	100.00%
CW4	57.10%
	[57.1%]
CW8	39.30%
BW6	89.30%
Others Found	
CW7	3.60%

(Chinese) Cell 1522	
(29 Samples Typed)	
A24	100.00%
	[100.0%]
A30	96.60%
A19	3.40%
	[100.0%]
B50	96.60%
B21	3.40%
	[100.0%]
B55	86.20%
B22	10.30%
	[96.6%]
CW3	48.30%
CW9	10.30%
	[58.6%]
CW6	51.70%
	[51.7%]
BW6	89.70%
Others Found	
B70	3.40%
B67	3.40%

(Caucasian) Cell 1523	
(27 Samples Typed)	
A3	100.00%
A69	77.80%
A28	22.20%
	[100.0%]
B38	96.30%
B16	3.70%
	[100.0%]
B55	92.60%
B22	7.40%
	[100.0%]
CW3	51.90%
CW9	11.10%
	[63.0%]
BW4	85.20%
BW6	88.90%
Others Found	
B56	3.70%
B52	3.70%
CW12	3.70%
A2	3.70%
CW5	3.70%

(Asian) Cell 1524	
(27 Samples Typed)	
A26	100.00%
	[100.0%]
A33	96.30%
	[96.3%]
B61	74.10%
B40	22.20%
B40V	3.70%
	[100.0%]
B55	81.50%
B22	11.10%
	[92.6%]
CW1	59.30%
CW3	51.90%
CW10	3.70%
CW9	7.40%
	[63.0%]
BW6	88.90%
Others Found	
B45	3.70%
A34	3.70%
B48	3.70%
A10	3.70%
A29	3.70%
CW7	3.70%
B56	3.70%

Table 15. Individual laboratory results for Cell #1521

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*02:06	*68:03	*35:12:01	*48:01:01	*04:01:01	*08:01:01	PCR-RSSO,SBT
774	Cecka,J.Michael	*02:06/278/290/328+	*68	*35	*48	*04	*08	SSP
8070	Chang,Uckjin	*02	*36	*35	*48	*04	*08	SSP
4492	Charron,D.	*02	*68	*35	*48	*04	*08	SSP
798	Claas,F.H.J.	*02:06	*68:03	*35:12:01	*48:01:01	*04:01:01	*08:01:01	SBT
3632	Colombe,Beth	*02:06	*68:08	*35:12	*48:01	*04:01	*08:01	SSO,SSP
779	Daniel,Claud	*02	*68:03	*35:12	*48	*04	*08	PCR-SSP,SSO
3766	Dunn,Paul	*02:06+	*68:03	*35:12	*48	*04	*08	SSO
5214	Eckels/CPMC	*02	*68:03	*35:12	*48	*04	*08	SSO
762	Fischer,Gottfried	*02	*68	*35	*48	*04	*08	SSO,SSP
4079	Fort,Marylise	*02	*68	*35	*48	*04	*08	SSP
9002	Gideoni_LR	*02	*68	*35	*48	*04	*08	SSO
3808	Hogan,Patrick	*02	*68:03-05/15+	*35:10/12/13/16+	*48	*04	*08	SSP
9003	Israel_LR	*02	*68	*35	*48	*04	*08	PCR-SSOP
168	Klein,Tirza	*02:06	*68:03	*35:12	*48:01	*04:01	*08:01	PCR-SSP,SSO
9000	Klein_LR	*02	*68	*35	*48	*04	*08	PCR-SSP,SSO
725	Lardy,N.M.	*02	*68	*35	*48	*04	*08	SSO,SSP
745	Latham, Katy	*02:06	*68:03	*35:12:01	*48:01:01	*04:01:01	*08:01:01	SSO,SSP,SBT
278	Lee,Jar-How	*02:06/278/405	*68:03	*35:12	*48:01	*04:01	*08:01/78	SSP,RSSO
6649	Lim,Young Ae	*02	*68	*35	*48			SSP
731	Loewenthal,R	*02:06	*68:03	*35:12:01	*48:01:01	*04:01:01	*08:01	SBT,SSO
759	Lopez-Cepero	*02:06/10/21/28/61+	*68:03	*35:12	*48:01/09/11/27+	*04:01/05/07/09N+	*08:01/08/20/21+	RSSO
54	Pancoska,Carol	*02	*68	*35	*48	*04	*08	RSSOP
8001	Rao,Prakash	*02	*68	*35	*48	*04	*08	RSSO,SSP
3625	Rees,Tracey	*02:06/331	*68:03/05	*35:12	*48:01	*04:01/30/82	*08:01	PCR-SSP,SBT
1160	Rosen-Bronson	*02:06/331	*68:03	*35:12	*48:01	*04	*08	SSO,SBT
793	Rubocki,Ronald	*02	*68	*35	*48	*04	*08	SSP
4251	Schiller,Jennifer	*02:06	*68:03	*35:12	*48:01	*04:01P	*08:01:01G	PCR-RSSO,SBT
3545	Scornik,Juan C	*02:06	*68:03	*35:12	*48:01	*04:01/09N/30/82	*08:01/22	SSOP,SBT
747	Tiercy,Jean-Marie	*02:06:01	*68:03:01	*35:12:01	*48:01:01	*04:01:01	*08:01	SSO,SSP,SBT
5462	Turner,E.V.	*02:06	*68:03	*35:12	*48:01	*04:01	*08:01	SBT,SSO,SSP
5642	Varnavidou-Nico	*02	*68	*35	*48	*04	*08	PCR-SSP
3186	Watson,Narelle	*02	*68	*35	*48	*04	*08	SSO

Table 16. Individual laboratory results for Cell #1522

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar, Medhat	*24:02	*30:01:01	*50:01:01	*55:02:01	*03:03/20N	*06:02/83	PCR-RSSO, SBT
774	Cecka, J. Michael	*24	*30	*50	*55	*03	*06	SSP
8070	Chang, Uckjin	*24	*30	*50	*55	*03	*12	SSP
4492	Charron, D.	*24	*30	*50	*55	*03:03	*06	SSP
798	Claas, F. H. J.	*24:02:01	*30:01:01	*50:01:01	*55:02:01	*03:03:01	*06:02:01	SBT
3632	Colombe, Beth	*24:02	*30:01	*50:01	*55:02	*03:03	*06:02	SSO, SSP
779	Daniel, Claud	*24	*30	*50	*55	*03 (CW9)	*06	PCR-SSP, SSO
3766	Dunn, Paul	*24	*30	*50	*55	*03	*06	SSO
5214	Eckels/CPMC	*24	*30	*50	*55	*03 (CW9)	*06	SSO
762	Fischer, Gottfried	*24	*30	*50	*55	*03	*06	SSO, SSP
4079	Fort, Marylise	*24	*30	*50	*55	*03	*06	SSP
9002	Gideoni_LR	*24	*30	*50	*55	*03	*06	SSO
3808	Hogan, Patrick	*24	*30	*50	*55	*03:03+	*06	SSP
9003	Israel_LR	*24	*30	*50	*55	*03	*06	PCR-SSOP
168	Klein, Tirza	*24:02	*30:01	*50:01	*55:02	*03:03	*06:02	PCR-SSP, SSO
9000	Klein_LR	*24	*30	*50	*55	*03	*06	PCR-SSP, SSO
725	Lardy, N. M.	*24	*30	*50	*55	*03	*06	SSO, SSP
745	Latham, Katy	*24:02	*30:01:01	*50:01:01	*55:02:01	*03:03	*06:02	SSO, SSP, SBT
278	Lee, Jar-How	*24:02/02Q/135	*30:01/73N/78N	*50:01/16/18	*55:02/48/57	*03:03/62/171	*06:02/46N/55	SSP, RSSO
6649	Lim, Young Ae	*24	*30	*50	*55			SSP
731	Loewenthal, R	*24:02/124	*30:01:01/11	*50:01:01	*55:02:01	*03:03	*06:02	SBT, SSO
759	Lopez-Cepero	*24:02/05/09N/11N+	*30:01/11/14L/15+	*50:01/08/10/11+	*55:02/12/16/19+	*03:03/11/12/20N+	*06:02/03/10/12+	RSSO
54	Pancoska, Carol	*24	*30	*50	*55	*03 (CW9)	*06	RSSOP
8001	Rao, Prakash	*24	*30	*50	*55	*03:03	*06	RSSO, SSP
3625	Rees, Tracey	*24:02	*30:01	*50:01	*55	*03:03	*06:02/83	PCR-SSP, SBT
1160	Rosen-Bronson	*24	*30	*50:01/13	*55:02/16	*03	*06	SSO, SBT
793	Rubocki, Ronald	*24	*30	*50	*55	*03 (CW9)	*06	SSP
4251	Schiller, Jennifer	*24:02	*30:01	*50:01	*55:02	*03:03:01G	*06:02P	PCR-RSSO, SBT
3545	Scornik, Juan C	*24:02	*30:01	*50:01	*55:02	*03:03/20N	*06:02/83	SSOP, SBT
747	Tiercy, Jean-Marie	*24:02	*30:01:01	*50:01:01	*55:02:01	*03:03:01	*06:02:01	SSO, SSP, SBT
5462	Turner, E. V.	*24:02	*30:01	*50:01	*55:02	*03:03	*06:02	SBT, SSO, SSP
5642	Varnavidou-Nico	*24	*30	*50	*55	*03	*06	PCR-SSP
3186	Watson, Narelle	*24	*30	*50	*55	*03:03/88	*06	SSO

Table 17. Individual laboratory results for Cell #1523

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar, Medhat	*03:01:01	*69:01	*38:01:01	*55:01:01	*03:03/20N	*12:03	PCR-RSSO, SBT
774	Cecka, J. Michael	*03	*69	*38	*55	*03	*12	SSP
8070	Chang, Uckjin	*03	*69	*38	*55	*03	*06	SSP
4492	Charron, D.	*03	*69	*38	*55	*03:03	*12	SSP
798	Claas, F. H. J.	*03:01:01	*69:01	*38:01:01	*55:01:01	*03:03:01	*12:03:01	SBT
3632	Colombe, Beth	*03:01	*69:01	*38:01	*55:01	*03:03	*12:03	SSO, SSP
779	Daniel, Claud	*03	*69:01	*38	*55	*03 (CW9)	*12	PCR-SSP, SSO
3766	Dunn, Paul	*03	*69:01	*38	*55	*03	*12	SSO
5214	Eckels/CPMC	*03	*69:01	*38	*55	*03 (CW9)	*12	SSO
762	Fischer, Gottfried	*03:01	*69:01	*38:01	*55:01	*03:03	*12:03	SSO, SBT
4079	Fort, Marylise	*03:01	*69:01	*38:01/32	*55:01	*03:03	*12:03/101/102	SSO, SSP
9002	Gideoni_LR	*03	*69	*38	*55	*03	*12	SSO
3808	Hogan, Patrick	*03	*69:01	*38	*55	*03:03+	*12:03+	SSP
9003	Israel_LR	*03	*69	*38	*55	*03	*12	PCR-SSOP
168	Klein, Tirza	*03:01	*69:01/02	*38:01	*55:01	*03:03	*12:03	PCR-SSP, SSO
9000	Klein_LR	*03	*69	*38	*55	*03	*12	PCR-SSP, SSO
725	Lardy, N. M.	*03	*69	*38	*55	*03	*12	SSO, SSP
745	Latham, Katy	*03:01:01	*69:01	*38:01/32	*55:01/02	*03:03	*12:03	SSO, SSP, SBT
278	Lee, Jar-How	*03:01/112/118	*69:01	*38:01/31/32	*55:01/55N/59	*03:03/62/171	*12:03/23/34	SSP, RSSO
6649	Lim, Young Ae	*03	*69	*38	*55			SSP
731	Loewenthal, R	*03:01:01	*69:01	*38:01:01	*55:01:01	*03:03/04	*12:03/58	SBT, SSO
759	Lopez-Cepero	*03:01/03N/04+	*69:01	*38:01/09/12/21+	*55:01/02/03/12+	*03:03/06/09/11+	*12:03/06/07/12+	RSSO
54	Pancoska, Carol	*03	*69	*38	*55	*03 (CW9)	*12	RSSOP
8001	Rao, Prakash	*03	*69	*38	*55	*03:03	*12	RSSO, SSP
3625	Rees, Tracey	*03:01	*69:01	*38:01	*55:01	*03:03	*12:03	PCR-SSP, SBT
1160	Rosen-Bronson	*03:01	*69:01	*38:01/14/32	*55	*03	*12	SSO, SBT
793	Rubocki, Ronald	*03	*69	*38	*55	*03 (CW9)	*12	SSP
4251	Schiller, Jennifer	*03:01	*69:01	*38:01	*55:01	*03:03:01G	*12:03:01G	PCR-RSSO, SBT
3545	Scornik, Juan C	*03:01/01N	*69:01	*38:01	*55:01	*03:03/20N	*12:03	SSOP, SBT
747	Tiercy, Jean-Marie	NT						SSO, SSP, SBT
5462	Turner, E. V.	*03:01	*69:01	*38:01	*55:01	*03:03	*12:03	SBT, SSO, SSP
5642	Varnavidou-Nico	*03	*69	*38	*55	*03	*12	PCR-SSP
3186	Watson, Narelle	*03	*69	*38	*55	*03:03/88	*12	SSO

Table 18. Individual laboratory results for Cell #1524

Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar, Medhat	*26:01:01	*33:03:01	*40:06	*55:02:01	*01:02	*03:03/20N	PCR-RSSO, SBT
774	Cecka, J. Michael	*26	*33	*40:06/86/103/127+	*55	*01	*03	SSP
8070	Chang, Uckjin	*26	*33	*40	*55	*01	*03	SSP
4492	Charron, D.	*26	*33	*40	*55	*01	*03:03	SSP
798	Claas, F.H.J.	*26:01:01	*33:03:01	*40:06	*55:02:01	*01:02	*03:03	SBT
3632	Colombe, Beth	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03	SSO, SSP
779	Daniel, Claud	*26	*33	*40 (B61)	*55	*01	*03 (CW9)	PCR-SSP, SSO
3766	Dunn, Paul	*26	*33	*40:04+	*55	*01	*03	SSO
5214	Eckels/CPMC	*26	*33	*40 (B61)	*55	*01	*03 (CW9)	SSO
762	Fischer, Gottfried	*26:01	*33:03	*40:06	*55:02	*01:02/85	*03:03	SSO, SBT
4079	Fort, Marylise	*26:01/85	*33:03/73N	*40:06	*55:02	*01:02	*03:03	SSO, SSP
9002	Gideoni_LR	*26	*33	*40	*55	*01	*03	SSO
3808	Hogan, Patrick	*26	*33	*40:02+	*55	*01	*03:03+	SSP
9003	Israel_LR	*26	*33	*40	*55	*01	*03	PCR-SSOP
168	Klein, Tirza	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03	PCR-SSP, SSO
9000	Klein_LR	*26	*33	*40	*55	*01	*03	PCR-SSP, SSO
725	Lardy, N.M.	*26	*33	*40	*55	*01	*03	SSO, SSP
745	Latham, Katy	*26:01:01	*33:03:01	*40:06	*55:02:01	*01:02	*03:03	SSO, SSP, SBT
278	Lee, Jar-How	*26:01/77/80	*33:03/03Q/25	*40:06/103/127	*55:02/57	*01:02/25/40	*03:03/62/171	SSP, RSSO
6649	Lim, Young Ae	*26	*33	*40 (B61)	*55			SSP
731	Loewenthal, R	*26:01:01	*33:03:01	*40:06	*55:02:01	*01:02/51	*03:03/04	SBT, SSO
759	Lopez-Cepero	*26:01/10/15/17+	*33:01/03/04/05+	*40:04/06/64/70+	*55:02/12/19/42+	*01:02/07/11/15+	*03:03/06/09/11+	RSSO
54	Pancoska, Carol	*26	*33	*40 (B61)	*55	*01	*03 (CW9)	RSSOP
8001	Rao, Prakash	*26	*33	*40:04/06/64/129	*55	*01	*03:03	RSSO, SSP
3625	Rees, Tracey	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03	PCR-SSP, SBT
1160	Rosen-Bronson	*26:01/09	*33:03/61	*40:06	*55:02	*01	*03	SSO, SBT
793	Rubocki, Ronald	*26	*33	*40 (B61)	*55	*01	*03 (CW9)	SSP
4251	Schiller, Jennifer	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03:01G	PCR-RSSO, SBT
3545	Scornik, Juan C	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03/20N	SSOP, SBT
747	Tiercy, Jean-Marie	NT						SSO, SSP, SBT
5462	Turner, E.V.	*26:01	*33:03	*40:06	*55:02	*01:02	*03:03	SBT, SSO, SSP
5642	Varnavidou-Nico	*26	*33	*40	*55	*01	*03	PCR-SSP
3186	Watson, Narelle	*26	*33	*40:04/06/64/129	*55	*01	*03:03/69/88	SSO

Table 19. Individual laboratory results for Cell #1521-1524

Investigator	Days Old	Cell No 1521 (Hispanic)									Cell No 1522 (Chinese)							Cell No 1523 (Caucasian)							Cell No 1524 (Asian)										
		Viab %	A2	A68	B35	B48	CW4	CW8	BW6	Viab %	A24	A30	B50	B55	CW3	CW6	BW6	OTHERS	Viab %	A3	A69	B38	B55	CW3	BW4	BW6	OTHERS	Viab %	A26	A33	B61	B55	CW1	CW3	BW6
Alvarez, Carr		80	+	+	+	+		+	80	+	+	+	+			+		80	+	+	+	+			+		80	+	+	+	+			+	
Askar, Medhat	2	95	+	+	+	+	+	+	95	+	+	+	+	+	+	+		95	+	+	+	+	+	+	+		95	+	+	+	B22	+	+	+	
Cecka, J. Mic		95	+	+	+	+		+	95	+	+	+	+			+		95	+	+	+	+		+	+		95	+	+	+	+			+	
Charron, Domi		100	+	+	+	+			100	+	+	+	+					100	+	+	+	+					100	+	+	B40	+				
Claas, F.H.J.	6	90	+	A28	+	+	+		90	+	+	+	+	+		+		90	+	+	+	+	+	+	+		90	+	+	+	+	+		+	
Dunn, Paul		95	+	+	+	+		+	95	+	+	+	+			+		95	+	+	+	+		+	+		95	+	+	+	+			+	
Enczmann, J		95	+	+	+	+			95	+	+	+	+					95	+	+	+	+					95	+	+	+	+				
Esteves Kondo		98	+	+	+	+	+	+	98	+	+	+	+	w9	+	+		98	+	+	+	+	w9	+	+		98	+	+	B40V	+	+	w9	+	
Fort, Marylis	3	98	+	+	+	+		+	95	+	+	+	+			+																			
Gideoni, Osna	7	90	+	+	+	+	+	+	90	+	+	+	+	+	+			90	+	+	+	+	+				90	+	+	+	+	+	+		
Hahn, Amy B.		99	+	+	+	+	+	+	99	+	+	+	+	w9	+	+		99	+	+	+	+	w9	+	+		99	+	+	+	+	+	w10	+	
Hesse, Kissel	6	95	+	+	+	+	+	+	90	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+	
Hogan, Patric		70	+	A28	+	+	+	w7	70	+	+	+	+	+	+	+		70	+	+	+	+	+	+	+		70	+	+	+	+	w7	+	+	
Kvam, Vonnett	3	95	+	A28	+	+	+	+	97	+	+	+	+	+	+	+		97	+	A28	+	+	+	+	+		95	+	+	+	+	+	+	+	
Latham, Katy		90	+	+	+	+			90	+	+	+	+					90	+	+	+	+					90	+	+	B40	+				
Loewenthal MD		90	+	A28	+	+	+	+	90	+	+	+	+	+	+	+		90	+	A28	+	+	+	+	+		90	+	+	+	+	+	+	+	
Mah, Helen	2	98	+	+	+	+	+	+	98	+	+	+	+	+	+	+		98	+	+	+	+	+	+	Cw12		98	+	+	+	+	+	+	+	
Meyer, Pieter		80	+	+	+	+	+	+	90	+	+	+	B67	+	+			90	+	+	B16	+	+	+	+		90	+	+	B40	B45	+	+	+	
Pancoska, Car	2	98	+	+	+	+	+	+	98	+	+	+	+	w9	+	+		97	+	+	+	+	w9	+	+		98	+	+	+	+	+	w9	+	
Permpikul, Ve		90	+	+	+	+		+	90	+	+	+	+			+		90	+	+	+	+		+	+		90	+	+	+	+			+	
Pollack, Mari	2	98	+		+	+	+	+	98	+	+	+	+	+	+	+		98	+	+	+	+	+	+	+		98	+	+	+	+	+	+	+	
Rees, Tracey	3	80	+	+	+	+	+	+	90	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+	
Renac, Virgin	3	99	+	A28	+	+		+	99	+	+	B21	B22			+		99	+	A28	+	B22		+	+		99	+	+	B40	B22			+	
Rosen-Bronson		85	+	+	+	+	+	+	85	+	+	+	+	+	+	+		85	+	+	+	+	+	+	+		85	+	+	+	+	+	+	+	
Rubocki, Rona		98	+	A28	+	+	+	+	98	+	+	+	+	+	+	+		98	+	A28	+	+	+	+	+		98	+	+	+	+	+	+	+	
Shai, Isaac	13								70	+	+	+	B22	+	+	+	B70	72	+	A28	+	+	+	+	A2 >	68	+	A29	B40	B56	+	+	+	B48>	
Tiercy, Jean-	6	70	+	A28	+	+		+	90	+	+	+	+			+		98	+	+	+	+		+	+		98	+	+	+	+			+	
Varnavidou-Ni	6	98	+		+	+		+	98	+	+	+	+			+		98	+	+	+	+		+	+		98	+	+	+	+			+	
Vidan-Jeras,	6	90	+	+	+	+	+	+	100	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+		95	+	+	+	+	+	+	+	
Watson, Narel	8	70	+	A28	+	+		+	60	+	A19	+	B22			+		70	+	A28	+	B22		+	+		70	+	+	B40	B22			+	

Serum Exchange #538

The results for Serum Exchange #538 (sera 1145 – 1148) are summarized in Tables 20-26 and individual laboratory results by method are listed in Tables

27-37. Sera positive to A2 and A11 were examined in this study.

1145	method	#labs	A2	A68	A69	A24	B57	B58	B50	A23	A31	A32	A26	B51	B27	B49	B35	B46	B75	B44	B45	B13	B41	B52	B60	B61	B63	B47	A3	A30	A33	A25	A29	A11	A74	Cw9	B78	Cw10	B53	B71	A34	B72	B77				
	NIH-Std	6	100	50	33		17																																								
	NIH-Ext	3	100	67																																											
	AHG	4	100	75	25	75	50	50	25	25					25																		25														
	Luminex	28	93	93	93	86	93	96	89	86	82	82	82	89	82	82	93	89	86	86	86	86	86	82	82	82	82	82	82	82	86				82	86				89	86	82	82	82			
	Flow	4	50	50	50	50	50	50	50		50			50	50	50	50			50	50	50	50	50	50	50	50	50		50																	
	ELISA	2	100	100	100	50	100	100	100	100	50	50	50	100		100				100											50	50		50													
	C1q	1	100	100	100	100	100	100	100									100																													
	Other	2	100	100	100	50				50	50	50	50																	50	50	50	50														

Sample 1145 was found to be strongly positive to A2 by all methods. Additional strong reactivity to A28 (A68, A69) was also reported. Reactivity to 1C specificities (A23, A24, A31), B17 (B57, B58), and B50 was detected by various methods. Additional strong reactivity to 5C specificities was reported by Luminex, Flow, and Elisa. Luminex and 1 lab using PRA beads reported this sample as positive for DQ3 (DQ7, DQ8, DQ9), DR7, DR9, and DR11.

1145	method	#labs	DR11	DR7	DR9	DQ7	DQ8	DQ9	DPW1
	NIH-Std	6	no antigens assigned						
	C1q	1	no antigens assigned						
	Luminex	24	67	67	58	63	54	58	10
	Other	2	50	50	50	50	50	50	

1146	method	#labs	DR53	DR10	DR14	DR1	DR9	DR4	DQ7	DQ8	DQ9	DQ4	DQ2	DQ3	DQ6	DR7	DR103
	NIH-Std	6	17														
	C1q	1	100						100	100	100						
	Luminex	22	64	73	73	68	68	64	55	64	64	73	50	9	9	55	
	Other			50	50	50	50	50									50

For **sample 1146**, strong reactivity to A2 and A68 was detected by all methods. Additional strong reactivity to 10C specificities was also reported by all methods, except NIH. Positivity to 5C and 8C antigens was detected by Luminex, Flow, and Elisa. C1q reported additional reactivity to C-locus antigens (Cw4, Cw6, Cw7, Cw17, Cw18). Luminex and C1q reported this sample as positive for DR53 and DQ3 (DQ7, DQ8, DQ9). Luminex and 1 lab reporting PRA results detected reactivity to DR1, DR4, DR9, DR10, and DR14.

1146	method	#labs	A2	A68	A69	A33	A25	A66	A34	A26	B51	B52	B35	B75	B38	B39	B18	B53	B63	B64	B65	B78	B50	B62	A11	A28	B56	B71	B72	A24	A36	B49	B8	A1	B77	B46	B54	A43	B59	A3	B57	B58	Cw17	Cw18	Cw4	Cw6	Cw7		
	NIH-Std	6	17	83	50																					17																							
	NIH-Ext	3	33	67			33																			33																							
	AHG	4	100	75	25	50	50	25	75	50						25										25																							
	Luminex	28	93	93	93	96	82	59	89	89	82	79	93	86	75	71	89	89	82	68	71	71	82	79	68		82	79	82	86	71	79	79	68	79	75	75	68	68	68									
	Flow	3	67	67		67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67				67	67	67	67	67																
	ELISA	2	100	100	100	100	100	100	100	100	50	100	100	100	100	100							100	100	100			100	100	100																			
	C1q	1	100	100	100	100	100	100	100	100					100																													100	100	100	100	100	
	Other	2	50	50	50						50	50	50				50	50																															

Sample 1147 was found to be strongly positive to A2 by all methods. Additional reactivity to 5C, 7C, and 10C specificities was reported by various methods. Luminex, C1q, and 1 lab using PRA beads reported this sample as positive to numerous DR antigens (DR8, DR11, DR12, DR13, DR14, DR17, DR18, DR52), as well as to DQ7. Additional reactivity to DQ8, DQ9, DR7, and DR9 was reported by Luminex and 1 lab using PRA beads. Luminex also reported reactivity to DQ2, DPw2 and DPw4.

1147	method	#labs	DR8	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DQ7	DQ8	DQ9	DR7	DR9	DPw2	DPw4	DQ2	DP18	DQ6
	NIH-Std	6	no antigens assigned																	
	C1q	1	100	100	100	100	100	100	100	100	100									
	Luminex	22	73	68	68	68	68	64	64	68	64	64	73	73	55	55	55	14	9	
	Other	2	50	50	50	50	50	50	50	50	50	50	50	50						

1147	method	#labs	A2	B57	B58	B50	A69	A11	B55	B41	B42	B60	A29	A68	B45	B49	B54	B67	B39	B37	B13	A32	A24	B59	B47	B38	B63	B51	B52	B17	A1	A23	A43	A74	B8	B18	B62	B44	A3	A25	A36	Cw15
	NIH-Std	5	100											20															20	A1	A23	A43	A74	B8	B18	B62	B44	A3	A25	A36	Cw15	
	NIH-Ext	3	100							33																																
	AHG	4	100	50	50	25	25	50	25	25	50	89	89	89	25														25													
	Luminex	28	89	89	93	79	89	75	93	89	89	89	79		93	82	86	75	65	89	75	75	36	71	82	75	65	65	50				75	46	93	65	54	43	61	68	50	71
	Flow	3	67	67	67	67	67	67	67	67	67	67	33	33	67		67	67	67	67	67	67	33		67	67	67			33	33	33	33									
	ELISA	2	100	100	100	100	100	50	100	100	100	100	50	50		100	100	100	100		50			100					50													
	C1q	1	100	100	100	100	100		100	100	100	100	100		100	100				100																						
	Other	2	100	50	50	50	50	50						50		50												50	50				50									

For **sample 1148**, strong reactivity to A11 was reported by all labs. Reactivity to A10 (A25, A26, A34, A66) was detected by all labs, except Anti-globulin. Additional strong reactivity to 1C, 7C, and 10C specificities was reported by various methods. Luminex, C1q, and 1 PRA lab reported this

sample as positive for DQ7, DQ8, DQ9, DR4, DR8, and DR11. Anti-DR13 reactivity was detected by Luminex and C1q. Additional positivity to a number of DQ, DR, and DP antigens was also reported by Luminex.

1148	method	#labs	A11	A25	A26	A66	A34	A3	A30	A32	A31	A68	A33	A36	A1	B42	B7	B81	B60	B41	A29	A80	A69	A74	B8	B48	B61	B38	B37	B35	A6601	A10	A43	Cw7	B75	B73	B18	B39	B44	B47	Cw18	Cw6	Cw10	B67
	NIH-Std	5	100	80	80	40	40																						20		20													
	NIH-Ext	3	100	100	100	67	67	67	33	33	67	33												33						33														
	AHG	4	50				25								25	25	25	25											25		25													
	Luminex	28	68	89	89	57	89	89	93	86	89	89	89	82	82	86	82	71	89	89	86	82	89	89	82	71	68	65	57	50		86	75	71	82						71	61	54	68
	Flow	3	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67	67																
	ELISA	2	100	100	100	100	100	100	50	100	100	50	100	50	50	100	100				100	100			100																			
	C1q	1	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100				100	100	100												
	Other	2	50	100	100	50	100		50	50		50	50	50						50	50		50																					

1148	method	#labs	DQ7	DQ8	DQ9	DR11	DR4	DR8	DR13	DR16	DQ9	DQ6	DR15	DR53	DQ4	DR103	DR12	DPw5	DR51	DP10	DP14	DP15	DP17	DP9	DQ3	DR14
	NIH-Std	6	no antigens assigned																							
	C1q	1	100	100	100	100	100	100	100																	
	Luminex	22	68	68	68	73	73	55	68	59	68	59	46	43	34	34	18	25	25	9	9	9	9	9	9	
	Other	2	50	50	50	50	50	50																		

Serum Exchange #539

The results for our second serum study, Serum Exchange #539 (sera 1149-1152), are summarized in Tables 38-44 and individual laboratory re-

sults by method are listed in Tables 45-55. Sera strongly positive to B12 (B44, B45) were examined in this study.

Sample 1149 was found to be strongly positive to B44 and B45 by all methods. Anti-B41, -B47, -B49, and -B50 reactivity, as well as positivity to 7C and 5C specificities were detected by various methods. In addition, Luminex and C1q reported reactivity to a number of C-locus antigens. Luminex and 1 lab using PRA beads reported class II reactivity to DQ3 (DQ7, DQ8, DQ9).

1149	method	#labs	DQ7	DQ8	DQ9	DQ3	DR4	DR10	DR7
	NIH-Std	5	no antigens assigned						
	C1q	1	no antigens assigned						
	Luminex	24	71	71	71			13	13
	Other	1	100	100	100	100	100		

1149	method	#labs	B44	B45	B49	B50	B41	B47	B60	B61	B13	B51	B35	A32	A2	B27	B53	B46	B57	B76	B75	B82	B18	B62	B56	B72	B58	B52	Cw6	Cw17	Cw2	Cw5	Cw10	Cw4	Cw15	Cw18	Cw8	Cw12	Cw9	B63			
	NIH-Std	7	86	43	29	14																																					
	NIH-Ext	3	100	100	67		33	33																																			
	AHG	4	100	100	100	100	75	25	100	100	25	25																															
	Luminex	30	93	93	93	93	97	93	93	83	83	70	87	83	93	77	73	77	70	77	63	67	83	80	73	73	73	63	87	80	80	80	70	87	83	80	77	73	73	63			
	Flow	2	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50		50	50	50	50	50	50	50	50	50																
	ELISA	2	100	50	100	50	50	50	50	50	100	50	50	50			50	50	50		50																					50	
	C1q	1	100	100	100	100	100	100	100	100	100									100		100							100	100	100	100											
	Other	3	67	67	67	67	67	67	67	67	67	33	33	33	67	33		33																									

1150	method	#labs	DR1	DR103	DR7	DR51	DQ4	DQ8	DR10	DR9	DR53	DQ6	DR4	DQ5	DR15
	NIH-Std	5	no antigens assigned												
	C1q	1					100	100							
	Luminex	24	83	73	75	58			75	73	67	17	17	13	13
	Other	1	100	100	100	100									

For **Sample 1150**, strong reactivity to B44 and B45 was detected by all methods, except Flow, which reported anti-Bw4 and -Bw6 reactivity. Additional reactivity to a number of 5C and 7C specificities was reported by various methods. ELISA and Luminex also detected positivity to B37, B38, B39, B47, and B59. Reactivity to a number of class II antigens (DR1, DR103, DR7, and DR51) was detected by Luminex and 1 lab using PRA beads. Additional reactivity to DR9, DR10, and DR53 was also reported by Luminex. C1q reported positivity to DQ4 and DQ8.

1150	method	#labs	B44	B45	B49	B50	B35	B62	B75	B72	B71	B53	B18	B41	B52	B51	B13	B48	B56	B37	B47	B76	B77	B78	B38	B39	B59	B60	B61	B63	B57	B46	B65	B58	B64	B8	B82	Bw4	Bw6	Cw10	Cw9		
	NIH-Std	7	86	71	71	57	29	57	14	43	29																																
	NIH-Ext	3	100	100	100	67	100	100	33	67	33			33	33	33																											
	AHG	4	100	75	100	100	100	75		50	50		25				25							50																			
	Luminex	30	87	100	90	87	97	90	87	90	77	90	93	90	83	83	80	87	83	80	80	80	77	77	77	63	67	93	90	73	73	70	70	63	63	63	50					33	32
	Flow	2																																									
	ELISA	2	100	100	100	50	50		100			50	50	100	50	50	100	50	50	50	50				50	50	50																
	C1q	1	100		100	100		100	100	100												100																					
	Other	3		33			33	33	33	33		33										33																					

Sample 1151 was reported to be strongly positive to B44 and B45 by all methods. Additional reactivity to B49 and B50 was also detected by various methods, along with reactivity to 1C, 7C, and 10C specificities. Anti-DR1 reactivity was reported by all methods reporting class II results. Addi-

tional positivity to DQ5, DQ6, DR9, DR10, and DR51 was reported by Luminex, C1q, and 1 PRA lab. Reactivity to DR103, DR14, DR15, DR16 and a number of DP antigens was also detected by various methods.

1151	method	#labs	B44	B45	B50	B49	A23	A24	A1	B60	B61	B41	B13	B47	B76	A32	A25	A34	A29	B27	B38	B75	B77	B82	B58	B7	B57	B59	B63	B37	B52	B64	B51	B55	B56	A43	B81	Cw4	A80	
	NIH-Std	7	71	57															14																					
	NIH-Ext	3	100	100	33	33																																		
	AHG	4	100	100	100	100	25	50	25	50	50	25	25																25											
	Luminex	29	93	93	93	79	97	93	79	90	90	93	83	93	79	69	66	62		69	66	66	66	66	62	59	59	59	59	55	55	62	59	59	59	55	52	48	72	
	Flow	2	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50		50	50	50	50											
	ELISA	2	100	100	50	100	50	50	50	100	50	50	100	50	50	50				50					50															
	C1q	1	100	100	100	100	100	100	100	100	100	100	100	100	100																									
	Other	2	50	50			50	50	50	50						50	50	50																						

1151	method	#labs	DR1	DQ5	DQ6	DR10	DR51	DR9	DR103	DR16	DR15	DR14	DPW1	DPW5	DPW6	DQ2	DR4	DP17	DPW3	DP13	DP14	DP15	DP18	DP10	DP11	DP9	DR18	DR52	DQ4	DC9	DR11							
	NIH-Std	5	14																																			
	C1q	1	100	100	100	100	100	100	100				100	100	100																							
	Luminex	22	77	82	77	77	63	55	73	64	59	45	59	59	50	73	63	55	55	50	50	50	50	45	45	45	18	18	14	14	14							
	Other	1	100	100	100	100	100	100		100	100	100																										

For **Sample 1152**, strong anti-B44 and –B45 reactivity was detected by all methods. Additional reactivity to other 12C antigens, along with 1C, 5C, and 7C specificities was reported by various methods. Luminex also reported reactivity to a number of C-locus antigens (Cw1, Cw8, Cw9, Cw10, Cw12, Cw16). DR7 and DR9 reactivity was detected by Luminex and 1 lab using PRA beads.

1152	method	#labs	DR7	DR9
	NIH-Std	5	no antigens assigned	
	C1q	1	no antigens assigned	
	Luminex	22	86	86
	Other	1	100	100

1152	method	#labs	B44	B45	B49	B50	B41	B60	B61	B13	B47	B62	B75	B46	B35	B64	B39	B72	B71	B76	A23	A1	A24	B82	B73	B48	B18	Cw1	Cw12	Cw8	Cw9	Cw10	Cw16	B78	Cw14	Cw7	A34	B8201	A31		
	NIH-Std	7	71	43																																					
	NIH-Ext	3	100	100	33		33	33																																	
	AHG	4	100	100	100	100	75	100	100	50	25	25				25																									
	Luminex	29	100	90	93	93	97	93	93	93	97	90	72	76	72	62	45	76	76	79	69	62	59	69	69	66	66	62	62	62	62	59	59	52	45	48	31	24	21		
	Flow	2	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	60	50		50	50	50	50	50									50					
	ELISA	2	100	50	50	50	100	100	50	100	50	50	100	50			50	50									50				50										
	C1q	1	100	100	100	100	100	100	100	100										100																					
	Other	2	50	50	50	50	50	50	50	50				50								50					50														

NEXT MAILING DATE: August 6, 2014

Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed

Table 20 . Summary of the 538th Serum Exchange (Serum #1145-1148) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
6 typing Labs			6 typing Labs			5 typing Labs			5 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	95%	A68	83%	100%	A2	100%	87%	A11	100%	58%
A68	50%	82%	A69	50%	100%	A68	20%	100%	A26	80%	92%
A69	33%	100%	A28	17%	100%	B17	20%	100%	A25	80%	80%
B57	17%	60%	A2	17%	71%				A66	40%	100%
									A34	40%	50%
									A10	20%	100%
									B35	20%	100%

Method: NIH-Extended											
*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	94%	A68	67%	67%	A2	100%	96%	A25	100%	100%
A68	67%	75%	A25	33%	100%	B41	33%	100%	A26	100%	100%
			A28	33%	100%				A11	100%	93%
			A2	33%	42%				A34	67%	100%
									A66	67%	100%
									A31	67%	89%
									A3	67%	30%
									A30	33%	100%
									A32	33%	100%
									A6601	33%	100%
									A6602	33%	100%
									A74	33%	100%
									A68	33%	50%

Table 21. Summary of the 538th Serum Exchange (Serum #1145-1148) by Antiglobulin and Other - class I

Method: Antiglobulin

*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
4 typing Labs			4 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	100%	A2	100%	100%	A11	50%	100%
A68	75%	100%	A34	75%	100%	B42	50%	100%	A1	25%	100%
A24	75%	91%	A68	75%	100%	B57	50%	100%	A10	25%	100%
B57	50%	100%	A25	50%	100%	A11	50%	86%	A23	25%	100%
B58	50%	100%	A26	50%	100%	B58	50%	83%	A3	25%	100%
A3	50%	94%	A33	50%	100%	A28	25%	100%	B13	25%	100%
A11	25%	100%	A11	25%	100%	A69	25%	100%	B35	25%	100%
A23	25%	100%	A28	25%	100%	B17	25%	100%	B42	25%	100%
A28	25%	100%	A66	25%	100%	B41	25%	100%	B55	25%	100%
A69	25%	100%	A69	25%	100%	B45	25%	100%	B7	25%	100%
B27	25%	100%	B17	25%	100%	B50	25%	100%	B81	25%	100%
B50	25%	100%	B39	25%	100%	B55	25%	100%	A2	25%	89%

Method: Other

*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A1	50%	100%	A2	100%	100%	A25	100%	100%
A68	100%	100%	A11	50%	100%	A11	50%	100%	A26	100%	100%
A69	100%	100%	A2	50%	100%	A23	50%	100%	A34	100%	100%
A11	50%	100%	A68	50%	100%	A24	50%	100%	A11	50%	100%
A23	50%	100%	A69	50%	100%	A32	50%	100%	A29	50%	100%
A24	50%	100%	B18	50%	100%	A68	50%	100%	A30	50%	100%
A25	50%	100%	B35	50%	100%	A69	50%	100%	A32	50%	100%
A26	50%	100%	B51	50%	100%	B49	50%	100%	A33	50%	100%
A29	50%	100%	B52	50%	100%	B50	50%	100%	A36	50%	100%
A3	50%	100%	B53	50%	100%	B51	50%	100%	A66	50%	100%
A31	50%	100%	B64	50%	100%	B52	50%	100%	A68	50%	100%
A32	50%	100%	B65	50%	100%	B57	50%	100%	A69	50%	100%
A33	50%	100%	B78	50%	100%	B58	50%	100%	B41	50%	100%

Table 22. Summary of the 538th Serum Exchange (Serum #1145-1148) by Luminex - class I

*** Serum 1145 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
B58	96%	100%
A2	93%	100%
A68	93%	100%
A69	93%	100%
B35	93%	100%
B57	93%	100%
B46	89%	100%
B50	89%	100%
B51	89%	100%
B53	89%	100%
A23	86%	100%
A24	86%	100%
A33	86%	100%
B41	86%	100%
B71	86%	100%
B75	86%	100%
CW9	86%	100%
B44	86%	90%
B13	86%	89%
B45	86%	80%
A26	82%	100%
A3	82%	100%
A30	82%	100%
A31	82%	100%
A32	82%	100%
A34	82%	100%
A74	82%	100%
B27	82%	100%
B47	82%	100%
B49	82%	100%
B52	82%	100%
B60	82%	100%
B61	82%	100%
B63	82%	100%
B72	82%	100%
B77	82%	100%

*** Serum 1146 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
A33	96%	90%
A2	93%	100%
A68	93%	100%
A69	93%	100%
B35	93%	100%
A26	89%	100%
A34	89%	100%
B18	89%	100%
B53	89%	100%
A24	86%	100%
B75	86%	100%
A25	82%	100%
B50	82%	100%
B51	82%	100%
B56	82%	100%
B63	82%	100%
B72	82%	100%
B49	79%	100%
B52	79%	100%
B62	79%	100%
B71	79%	100%
B77	79%	100%
B8	79%	86%
B38	75%	100%
B46	75%	100%
B54	75%	100%
A36	71%	100%
B39	71%	100%
B65	71%	100%
B78	71%	100%
A11	68%	100%
A43	68%	100%
B59	68%	100%
B64	68%	100%
A3	68%	89%
A1	68%	83%

*** Serum 1147 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
B45	93%	100%
B55	93%	100%
B58	93%	100%
B8	93%	100%
A2	89%	100%
A69	89%	100%
B37	89%	100%
B41	89%	100%
B42	89%	100%
B57	89%	100%
B60	89%	100%
B54	86%	100%
B47	82%	100%
B49	82%	100%
B50	79%	100%
A29	79%	93%
A11	75%	100%
A43	75%	100%
B38	75%	100%
B67	75%	100%
A32	75%	86%
B13	75%	67%
B59	71%	100%
CW15	71%	100%
A25	68%	80%
B18	65%	100%
B39	65%	100%
B51	65%	90%
B63	65%	83%
A3	61%	75%
B62	54%	100%
A36	50%	100%
B52	50%	100%
A74	46%	100%
B44	43%	50%
A24	36%	100%

*** Serum 1148 ***		
28 typing Labs		
Antigen	Consensus	Inclusion
A30	93%	100%
A25	89%	100%
A26	89%	100%
A3	89%	100%
A31	89%	100%
A33	89%	100%
A34	89%	100%
A68	89%	100%
A69	89%	100%
A74	89%	100%
B41	89%	100%
B60	89%	100%
A29	86%	100%
A32	86%	100%
A43	86%	100%
B42	86%	100%
A1	82%	100%
A36	82%	100%
A80	82%	100%
B7	82%	100%
B8	82%	100%
B73	82%	80%
CW7	75%	100%
B48	71%	100%
B81	71%	100%
CW18	71%	100%
B75	71%	62%
A11	68%	100%
B61	68%	89%
B67	68%	80%
B38	65%	100%
CW6	61%	100%
A66	57%	100%
B37	57%	100%
CW10	54%	100%
A6601	50%	100%

Table 23. Summary of the 538th Serum Exchange (Serum #1145-1148) by Flow Cytometry - class I

Method: Flow Cytometry											
*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
4 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	50%	100%	A2	67%	100%	A11	67%	100%	A1	67%	100%
A24	50%	100%	A24	67%	100%	A2	67%	100%	A11	67%	100%
A30	50%	100%	A25	67%	100%	A32	67%	100%	A25	67%	100%
A31	50%	100%	A26	67%	100%	A69	67%	100%	A26	67%	100%
A68	50%	100%	A33	67%	100%	B13	67%	100%	A3	67%	100%
A69	50%	100%	A34	67%	100%	B37	67%	100%	A30	67%	100%
B13	50%	100%	A36	67%	100%	B38	67%	100%	A31	67%	100%
B18	50%	100%	A66	67%	100%	B39	67%	100%	A32	67%	100%
B27	50%	100%	A68	67%	100%	B42	67%	100%	A33	67%	100%
B35	50%	100%	B18	67%	100%	B45	67%	100%	A34	67%	100%
B37	50%	100%	B35	67%	100%	B47	67%	100%	A36	67%	100%
B41	50%	100%	B38	67%	100%	B50	67%	100%	A66	67%	100%
B44	50%	100%	B39	67%	100%	B54	67%	100%	A68	67%	100%
B45	50%	100%	B49	67%	100%	B55	67%	100%	B18	67%	100%
B47	50%	100%	B50	67%	100%	B57	67%	100%	B37	67%	100%
B49	50%	100%	B51	67%	100%	B58	67%	100%	B38	67%	100%
B50	50%	100%	B52	67%	100%	B60	67%	100%	B39	67%	100%
B51	50%	100%	B53	67%	100%	B63	67%	100%	B41	67%	100%
B52	50%	100%	B57	67%	100%	B67	67%	100%	B42	67%	100%
B55	50%	100%	B58	67%	100%	A1	33%	100%	B44	67%	100%
B56	50%	100%	B62	67%	100%	A23	33%	100%	B47	67%	100%
B57	50%	100%	B63	67%	100%	A24	33%	100%	B48	67%	100%
B58	50%	100%	B64	67%	100%	A29	33%	100%	B60	67%	100%
B60	50%	100%	B65	67%	100%	A43	33%	100%	B61	67%	100%
B61	50%	100%	B75	67%	100%	A68	33%	100%	B7	67%	100%
B63	50%	100%	B8	67%	100%	A74	33%	100%	B81	67%	100%

Table 24. Summary of the 538th Serum Exchange (Serum #1145-1148) by ELISA + C1q - class I

Method: ELISA											
*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	100%	A2	100%	100%	A11	100%	100%
A23	100%	100%	A25	100%	100%	A69	100%	100%	A25	100%	100%
A68	100%	100%	A33	100%	100%	B39	100%	100%	A26	100%	100%
A69	100%	100%	A34	100%	100%	B41	100%	100%	A29	100%	100%
B49	100%	100%	A66	100%	100%	B42	100%	100%	A3	100%	100%
B50	100%	100%	A68	100%	100%	B49	100%	100%	A31	100%	100%
B51	100%	100%	A69	100%	100%	B50	100%	100%	A32	100%	100%
B57	100%	100%	B35	100%	100%	B54	100%	100%	A33	100%	100%
B58	100%	100%	B39	100%	100%	B55	100%	100%	A34	100%	100%
B75	100%	100%	B50	100%	100%	B57	100%	100%	A66	100%	100%
B78	100%	100%	B51	100%	100%	B58	100%	100%	A80	100%	100%
A24	50%	100%	B52	100%	100%	B59	100%	100%	B42	100%	100%
A25	50%	100%	B56	100%	100%	B60	100%	100%	B60	100%	100%
A26	50%	100%	B62	100%	100%	B67	100%	100%	B7	100%	100%
A29	50%	100%	B71	100%	100%	A1	50%	100%	B8	100%	100%
A3	50%	100%	B75	100%	100%	A11	50%	100%	B81	100%	100%
A31	50%	100%	B78	100%	100%	A29	50%	100%	A1	50%	100%
A32	50%	100%	B72	100%	67%	A68	50%	100%	A30	50%	100%
A74	50%	100%	A26	50%	100%	B13	50%	100%	A36	50%	100%
A80	50%	100%	B38	50%	100%	B27	50%	100%	A68	50%	100%

Method: C1q											
*** Serum 1145 ***			*** Serum 1146 ***			*** Serum 1147 ***			*** Serum 1148 ***		
1 typing Labs			1 typing Labs			1 typing Labs			1 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

Table 25 . Summary of the 538th Serum Exchange (Serum #1145-1148) by NIH-Standard, Other, and C1q - class II

Method: NIH-Standard															
*** Serum 1145 ***				*** Serum 1146 ***				*** Serum 1147 ***				*** Serum 1148 ***			
1 typing Labs				1 typing Labs				1 typing Labs				1 typing Labs			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no antigens assigned				no consensus				no antigens assigned				no antigens assigned			

Method: Other															
*** Serum 1145 ***				*** Serum 1146 ***				*** Serum 1147 ***				*** Serum 1148 ***			
1 typing Labs				1 typing Labs				1 typing Labs				1 typing Labs			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no antigens assigned				no consensus				no consensus				no consensus			

Method: C1q															
*** Serum 1146 ***				*** Serum 1146 ***				*** Serum 1147 ***				*** Serum 1148 ***			
1 typing Labs				1 typing Labs				1 typing Labs				1 typing Labs			
Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion		Antigen	Consensus	Inclusion	
no antigens assigned				no consensus				no consensus				no consensus			

Table 26. Summary of the 538th Serum Exchange (Serum #1145-1148) by Luminex - class II

*** Serum 1145 ***		
16 typing Labs		
Antigen	Consensus	Inclusion
DR11	100%	100%
DR7	100%	100%
DQ7	94%	100%
DQ9	88%	100%
DR9	88%	100%
DQ8	81%	100%
DPW1	19%	100%

*** Serum 1146 ***		
16 typing Labs		
Antigen	Consensus	Inclusion
DQ4	100%	100%
DR10	100%	100%
DR14	100%	75%
DR1	94%	100%
DR9	94%	100%
DQ8	88%	100%
DQ9	88%	100%
DR4	88%	100%
DR53	88%	100%
DR7	75%	100%
DQ7	75%	80%
DQ2	69%	100%
DQ3	13%	100%
DQ6	13%	100%

*** Serum 1147 ***		
16 typing Labs		
Antigen	Consensus	Inclusion
DR7	100%	100%
DR8	100%	100%
DR9	100%	100%
DR11	94%	100%
DR12	94%	100%
DR13	94%	100%
DR14	94%	100%
DR52	94%	100%
DQ7	88%	100%
DQ8	88%	100%
DQ9	88%	100%
DR17	88%	100%
DR18	88%	100%
DQ4	88%	92%
DPW2	75%	100%
DPW4	75%	100%
DQ2	75%	73%
DP18	19%	100%
DQ6	13%	100%

*** Serum 1148 ***		
16 typing Labs		
Antigen	Consensus	Inclusion
DR11	100%	100%
DR4	100%	100%
DR8	94%	100%
DQ7	88%	100%
DQ8	88%	100%
DQ9	88%	100%
DR13	88%	83%
DR16	81%	100%
DQ6	50%	100%
DR15	50%	33%
DR53	44%	100%
DQ4	31%	100%
DR103	31%	100%
DR12	25%	100%
DPW5	19%	100%
DR51	19%	100%
DP10	13%	100%
DP14	13%	100%
DP15	13%	100%
DP17	13%	100%
DP9	13%	100%
DQ3	13%	100%
DR14	13%	100%

Table 27. Individual laboratory results for Serum #1145-1148 by NIH-Standard and NIH-Extended

	**** Serum 1145 ****						**** Serum 1146 ****				**** Serum 1147 ****			**** Serum 1148 ****																
Investigator	% POS	A2	A68	A69	B57	Other	% POS	A68	A69	Other	% POS	A2	Other	% POS	A11	A26	A25	A66	A34											Method
Claas, F.H.J.	39	+	+				35	+			52	+	A68	39	+	+	+												STD	
Fort, Marylise	43	+	+	+			46	+	+	A2																			STD	
McCluskey, James	31	+	+	+			17	+	+		21	+		34	+	+	+		+										STD	
Reed, Elaine F. PhD	31	+					13	+	+		35	+		33	+	+	+	+	+										STD	
Suciu-Foca, Nicole I	33	+					17			A28	39	+	B17	50	+													A10,B35	STD	
Watson, Narelle	41	+			+		5	+			36	+		26	+	+	+	+											STD	

	**** Serum 1145 ****						**** Serum 1146 ****				**** Serum 1147 ****			**** Serum 1148 ****																
Investigator	% POS	A2	A68			Other	% POS	A68		Other	% POS	A2	Other	% POS	A25	A26	A11	A34	A66	A31	A3	Other								Method
Askar, Medhat Z. M	37	+	+				11	+		A25	46	+	B41	57	+	+	+			+	+		A74,A6601,A6602						EXT	
Dunn, Paul	47	+	+				42	+		A2	37	+		51	+	+	+	+	+	+	+		A30,A32,A68						EXT	
Lardy, N.M.	39	+					17			A28	41	+		28	+	+	+	+	+										EXT	

Table 28. Individual laboratory results for Serum #1145-1148 by Antiglobulin and Other

Investigator	**** Serum 1145 ****								**** Serum 1146 ****								**** Serum 1147 ****						**** Serum 1148 ****				Method	
	% POS	A2	A68	A24	B57	B58	A3	Other	% POS	A2	A34	A68	A25	A26	A33	Other	% POS	A2	B42	B57	A11	B58	Other	% POS	A11	Other		
Cecka, J. Michael P	80	+	+	+	+	+	+	B50,B27,B55>	65	+	+	+	+	+	+	B39	72	+	+	+	+	+	B50,B4,B55>	98			AHG	
Hahn, Amy B. PhD		+	+	+	+	+	+	A11		+	+	+				A11,A24,A3		+		+	+	+		+		A2,B13,B7>	AHG	
Mah, Helen	69	+	+					A1,A69	72	+	+	+	+	+	+	A66,A69	62	+	+				A68,A69,B41	86			AHG	
Suciu-Foca, Nicole I	52	+		+				A28	35	+						A28,B17	45	+					A28,B17	40	+		A10,B35	AHG

Investigator	**** Serum 1145 ****						**** Serum 1146 ****							**** Serum 1147 ****						**** Serum 1148 ****				Method			
	% POS	A2	A68	A69		Other	% POS	A1	A11	A2	A68	A69	B18	Other	% POS	A2					Other	% POS	A25		A26	A34	Other
Phelan, Donna		+	+	+		A11,A24,B60>		+	+	+	+	+	+	B35,B51,B52>		+					A11,A24,B62>		+	+	+	A11,B60,B48>	Other
Reed, Elaine F. PhL	98	+	+	+		B57,B58	94								82	+						96	+	+	+	A66	Other

Table 29. Individual laboratory results for Serum #1145 by Luminex

		**** Serum 1145 ****																																									
Investigator	% POS	B58	A2	A68	A69	B35	B57	B46	B50	B51	B53	A23	A24	A33	B41	B71	B75	CW9	B44	B13	B45	A26	A3	A30	A31	A32	A34	A74	B27	B47	B49	B52	B60	B61	B63	B72	B77	Other	Method				
Alvarez, Carretto &	36	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+	+								+	+	+	+			+	+	+	+	CW4,B48,B62,B7 >	LMX			
Askar, Medhat Z. M	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A203,B48 >	LMX			
Askar/WV,	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,B78 >	LMX			
Brouard, Tabary/Ph	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A203,B48,B78 >	LMX			
Cecka, J. Michael P	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B78 >	LMX			
Chen, Dong-Feng	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B48 >	LMX			
Dunn, Paul	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A203,B48 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B48 >	LMX		
Gideoni, Osnat	100	+	+	+	+	+	+		+	+	+	+	+	+	+		+													+					+	+			B78,A1,B37,B8	LMX			
Guerra, Q.F.B. Elba	d																																							LMX			
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX		
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A66,B78 >	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B48 >	LMX	
Klein, Tirza	63	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,B62,B82 >	LMX		
Lardy, N.M.		+	+	+	+	+	+			+		+	+		+		+		+	+	+	+			+	+	+	+										+	+	CW4,A66,A25,A43 >	LMX		
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A203,B48 >	LMX	
Mani, Rama	100	+										+		+									+	+												+			CW6,B8,CW1,CW3 >	LMX			
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX	
Meyer, Pieter Wa	55	+	+	+	+	+	+	+	+	+						+	+	+												+	+	+	+								CW4,B40,B15,B48 >	LMX	
Pancoska, Carol Ph	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B48 >	LMX
Reed, Elaine F. PhL		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B48,A66 >	LMX
Rosen-Bronson, Sai	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B48 >	LMX
Suciu-Foca, Nicole I	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A203,B48 >	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+		+	+	+		+	+	+					+	+	+	+	+	+	+							+	+	+	+	+	A11,A25,A29,A80 >	LMX	

Table 30. Individual laboratory results for Serum #1146 by Luminex

		**** Serum 1146 ****																																									
Investigator	% POS	A33	A2	A68	A69	B35	A26	A34	B18	B53	A24	B75	A25	B50	B51	B56	B63	B72	B49	B52	B62	B71	B77	B8	B38	B46	B54	A36	B39	B65	B78	A11	A43	B59	B64	A3	A1	A66	Other	Method			
Alvarez, Carretto &	61	+	+	+	+	+	+	+	+	+	+	+	+				+																							A2403,B7801 >	LMX		
Askar, Medhat Z. M	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A30,A74 >	LMX		
Askar/WV,	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,B57,B58 >	LMX		
Brouard, Tabary/Ph	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A74,B37,B41 >	LMX		
Cecka, J. Michael P	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Chen, Dong-Feng	NT																																								LMX		
Dunn, Paul	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A30,A74,B37 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,B57,B58 >	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67,A30,A74,B57 >	LMX	
Gideoni, Osnat	94	+	+	+		+	+		+	+	+	+		+	+				+	+	+			+					+	+	+									B57,B58,B73 >	LMX		
Guerra, Q.F.B. Elba																																									LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,CW10	LMX	
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10,CW9	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,B57,B58 >	LMX
Klein, Tirza	34	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,B41,A6601 >	LMX	
Lardy, N.M.		+	+	+	+	+	+	+		+																														+		LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B55,B67 >	LMX
Mani, Rama		+	+		+																																		+	A30,BW4,CW1	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67,A30,A74,A80 >	LMX	
Meyer, Pieter Wa	24	+		+	+	+	+	+	+		+					+																							+	A2C	LMX		
Pancoska, Carol Ph	56	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,CW10 >	LMX
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10,CW9	LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,BW4 >	LMX
Reed, Elaine F. PhL		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A74	LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,A74,CW10 >	LMX
Suciu-Foca, Nicole I	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A30,A74 >	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403,B7801,A1101 >	LMX

Table 31. Individual laboratory results for Serum #1147 by Luminex

		**** Serum 1147 ****																																							
Investigator	% POS	B45	B55	B58	B8	A2	A69	B37	B41	B42	B57	B60	B54	B47	B49	B50	A29	A11	A43	B38	B67	A32	B13	B59	CW15	A25	B18	B39	B51	B63	A3	B62	A36	B52	A74	B44	A24	Other	Method		
Alvarez, Carretto & Askar, Medhat Z. M	21	+	+	+	+	+	+	+	+	+	+	+	+	+																										A1101,A1102	LMX
Askar/WV,	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B27,B65,B72 >	LMX
Brouard, Tabary/Ph	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,A33	LMX
Cecka, J. Michael P	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B65,B72,CW17 >	LMX
Chen, Dong-Feng	82	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B65,B72,CW17 >	LMX
Dunn, Paul	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,B27,B82,A30 >	LMX
Eckels/CPMC,	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B27,A33,A23 >	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27	LMX
Gideoni, Osnat	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B61,B56	LMX
Guerra, Q.F.B. Elba																																									LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27	LMX
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,B27,A33,A23 >	LMX
Klein, Tirza	60	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,B27,B53,B82 >	LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A203,A33,A23 >	LMX
Mani, Rama		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A33,CW17	LMX
Martinho, Paiva & Meyer, Pieter Wa	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Pancoska, Carol Ph	42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,A2C	LMX
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A33,A23,B72	LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B3901	LMX
Reed, Elaine F. PhL		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A23,B65	LMX
Suciu-Foca, Nicole I	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A203,B27,A33 >	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1101,A1102,B3901	LMX

Table 32. Individual laboratory results for Serum #1148 by Luminex

		**** Serum 1148 ****																																									
Investigator	% POS	A30	A25	A26	A3	A31	A33	A34	A68	A69	A74	B41	B60	A29	A32	A43	B42	A1	A36	A80	B7	B8	B73	CW7	B48	B81	CW18	B75	A11	B61	B67	B38	CW6	A66	B37	CW10	A6601	A6602	Other	Method			
Alvarez, Carretto &	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,A1101,A1102	LMX
Askar, Medhat Z. M	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX
Askar/WV,	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX
Brouard, Tabary/Ph	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX
Cecka, J. Michael P	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39	LMX	
Chen, Dong-Feng	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B49,B50,B13 >	LMX	
Dunn, Paul	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B47,B44,B77,B39 >	LMX	
Fort, Marylise																																									LMX		
Gideoni, Osnat	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B13,B44	LMX	
Guerra, Q.F.B. Elba																																									LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX	
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B49,B50,B13 >	LMX	
Klein, Tirza	52	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B27,B64,B65 >	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B49,B50,B13 >	LMX
Mani, Rama		+											+							+					+															BW4,CW1	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX	
Meyer, Pieter Wa	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,CW17,B8C,B7C	LMX	
Pancoska, Carol Ph	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39	LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B47,B77,B39,CW9 >	LMX	
Reed, Elaine F. PhL		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B50,B47,B44,B77 >	LMX	
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B47,B44 >	LMX	
Suciu-Foca, Nicole I	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B49,B50,B13,B47 >	LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,A1101,A1102	LMX	

Table 33 . Individual laboratory results for Serum #1145-1148 by Flow Cytometry

		**** Serum 1145 ****																																			
Investigator	% POS	A2	A24	A30	A31	A68	A69	B13	B18	B27	B35	B37	B41	B44	B45	B47	B49	B50	B51	B52	B55	B56	B57	B58	B60	B61	B63	B64	B65	B67	B71	B72	B75	Other	Method		
Brouard, Tabary/PhD	95																																				FC
Eckels/CPMC,	99																																				FC
Esteves Kondo, Det	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,B54,B42,B59	FC
Reed, Elaine F. PhD	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B78 >	FC

		**** Serum 1146 ****																																					
Investigator	% POS	A2	A24	A25	A26	A33	A34	A36	A66	A68	B18	B35	B38	B39	B49	B50	B51	B52	B53	B57	B58	B62	B63	B64	B65	B75	B8									Other	Method		
Eckels/CPMC,	96																																						FC
Esteves Kondo, Det	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61,B27,B67 >	FC	
Reed, Elaine F. PhD	84	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B78,A74,A43 >	FC	

		**** Serum 1147 ****																																					
Investigator	% POS	A11	A2	A32	A69	B13	B37	B38	B39	B42	B45	B47	B50	B54	B55	B57	B58	B60	B63	B67																	Other	Method	
Eckels/CPMC,	97																																						FC
Esteves Kondo, Det	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B27,A1,A23 >	FC	
Reed, Elaine F. PhD	88	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B49,B51,B52 >	FC	

		**** Serum 1148 ****																																					
Investigator	% POS	A1	A11	A25	A26	A3	A30	A31	A32	A33	A34	A36	A66	A68	B18	B37	B38	B39	B41	B42	B44	B47	B48	B60	B61	B7	B81									Other	Method		
Eckels/CPMC,	99																																						FC
Esteves Kondo, Det	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B13,B27,B45,B67 >	FC
Reed, Elaine F. PhD	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B50,B75,A29,A74 >	FC

Table 34. Individual laboratory results for Serum #1145-1148 by Elisa and C1q

**** Serum 1145 ****														**** Serum 1146 ****																				
Investigator	% POS	A2	A23	A68	A69	B49	B50	B51	B57	B58	B75	B78	Other	% POS	A2	A25	A33	A34	A66	A68	A69	B35	B39	B50	B51	B52	B56	B62	B71	B75	B78	B72	Other	Method
Esteves Kondo, Dek	64	+	+	+	+	+	+	+	+	+	+	+	B60,B61,B62 >	67	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7,B55,B67>	Elisa
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	A11,A24,B13>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,B54,A26>	Elisa

**** Serum 1147 ****														**** Serum 1148 ****																					
Investigator	% POS	A2	A69	B39	B41	B42	B49	B50	B54	B55	B57	B58	B59	B60	B67	Other	% POS	A11	A25	A26	A29	A3	A31	A32	A33	A34	A66	A80	B42	B60	B7	B8	B81	Other	Method
Esteves Kondo, Dek	71	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B61,B62,B13>	89	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B62,B27>	Elisa
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B45,A29>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,B75,A1>	Elisa

**** Serum 1145 ****														**** Serum 1146 ****																				
Investigator	% POS	A2	A24	A68	A69	B46	B57	B58	CW10	CW9			Other	% POS	A2	A25	A26	A33	A34	A66	A68	A69	B38	B51	B63	B75	B77	CW17	CW18	CW4	CW6	CW7	Other	Method
Phelan, Donna		+	+	+	+	+	+	+	+	+					+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		C1q

**** Serum 1147 ****														**** Serum 1148 ****																						
Investigator	% POS	A2	A29	A69	B37	B41	B42	B45	B49	B50	B55	B57	B58	B60	Other	% POS	A11	A25	A26	A29	A3	A30	A31	A32	A33	A34	A43	A66	A68	A69	A74	B41	B42	B48	Other	Method
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B7,B8,B81	C1q	

Table 35. Individual laboratory results for Serum #1145-1148 by NIH-Standard, Other, and C1q - class II

		**** Serum 1145 ****		**** Serum 1146 ****							**** Serum 1147 ****								**** Serum 1148 ****										
Investigator	% POS	no antigens assigned		% POS	DR53					Other	% POS	no antigens assigned								% POS	no antigens assigned							Method	
Clas, F.H.J.				35	+																								STD

		**** Serum 1145 ****		**** Serum 1146 ****							**** Serum 1147 ****											**** Serum 1148 ****									
Investigator	% POS	no antigens assigned		% POS	DR1	DR10	DR103	DR14	DR4	DR9	Other	% POS	DQ7	DQ8	DQ9	DR11	DR12	DR13	DR14	DR7	DR8	Other	% POS	DQ7	DQ8	DQ9	DR11	DR4	DR8	Other	Method
Phelan, Donna					+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	DR9,DR17>		+	+	+	+	+	+		Other

		**** Serum 1145 ****		**** Serum 1146 ****							**** Serum 1147 ****											**** Serum 1148 ****									
Investigator	% POS	no antigens assigned		% POS	DQ7	DQ8	DQ9	DR53		Other	% POS	DQ7	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DR8	Other	% POS	DQ7	DQ8	DQ9	DR11	DR13	DR4	DR8	Other	Method
Phelan, Donna					+	+	+	+				+	+	+	+	+	+	+	+	+			+	+	+	+	+	+		C1q	

Table 36. Individual laboratory results for Serum #1145-1146 by Luminex - class II

Investigator	**** Serum 1145 ****								**** Serum 1146 ****													Method		
	% POS	DR11	DR7	DQ7	DQ9	DR9	DQ8	Other	% POS	DQ4	DR10	DR14	DR1	DR9	DQ8	DQ9	DR4	DR53	DR7	DQ7	DQ2		Other	
Askar, Medhat Z. M	100	+	+	+	+	+	+		100	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Askar/WV,	99	+	+	+	+	+	+		99	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Chen, Dong-Feng	Multi	+	+	+	+	+	+		NT															LMX
Eckels/CPMC,		+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Fort, Marylise		+	+	+	+	+	+	DR8,DR13,DPW1		+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Hahn, Amy B. PhD		+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Holdsworth, Rhonda		+	+	+	+	+	+	DR52,DPW1		+	+	+	+	+	+	+	+	+		+	+			LMX
Klein, Tirza	63	+	+	+	+	+	+		34	+	+	+	+	+			+		+				DQ3,DQ6	LMX
Mani, Rama	100	+	+	+	+					+	+	+	+		+	+		+		+				LMX
Meyer, Pieter Wa	55	+	+			+		DR3,DQ1,DQ3,DQ5	24	+	+	+	+	+					+				DQ3,DQ6	LMX
Pancoska, Carol Ph	85	+	+	+	+	+	+		56	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Permpikul, Vejbaesy		+	+	+		+		DR12		+	+	+	+	+	+	+	+	+	+				DR8	LMX
Phelan, Donna		+	+	+	+	+	+	DPW1		+	+	+	+	+	+	+	+	+		+	+			LMX
Ramon, Daniel PhD		+	+	+	+		+			+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai	100	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+					LMX
Turner, E.V. PhD		+	+	+	+	+	+			+	+	+		+	+	+	+	+		+	+			LMX
Vather, Nelson/										+	+	+	+	+	+	+	+	+	+	+	+	+		LMX

Table 37. Individual laboratory results for Serum #1147-1148 by Luminex - class II

Investigator	**** Serum 1147 ****																**** Serum 1148 ****											Method							
	% POS	DR7	DR8	DR9	DR11	DR12	DR13	DR14	DR52	DQ7	DQ8	DQ9	DR17	DR18	DQ4	DPW2	DPW4	DQ2	Other	% POS	DR11	DR4	DR8	DQ7	DQ8	DQ9	DR13		DR16	DQ6	DR15	DR53	Other		
Askar, Medhat Z. M	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		98	+	+	+	+	+	+	+	+	+	+	+			LMX	
Askar/WV,	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		97	+	+	+	+	+	+	+	+	+	+	+			LMX	
Chen, Dong-Feng	Multi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DP11,DP18	Multi	+	+	+	+	+	+	+	+	+	+	+	+	DR103,DR12,DPW5,DP9 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX		
Fort, Marylise																																	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DP18		+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DPW1,DPW3,DQ4		+	+	+	+	+	+	+	+	+	+	+	+	DR103,DR12,DQ4,DPW5 >	LMX	
Klein, Tirza	60	+	+	+	+	+	+	+					+	+	+				DR15,DQ3	52	+	+	+				+	+	+	+	+	+	DR51,DR52,DQ3,DQ4	LMX	
Mani, Rama		+	+	+					+	+	+	+			+						+	+	+	+	+							DR103,DQ4	LMX		
Meyer, Pieter Wa	19	+	+	+	+	+	+	+							+			+	DR2,DR3,DQ3	30	+	+	+				+	+	+	+	+	+	DR14,DQ3	LMX	
Pancoska, Carol Ph	42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		46	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ6		+	+	+	+	+								DR103,DR12,DR14,DR51	LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DP18		+	+	+	+	+	+	+	+	+	+	+	+			LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+		+	+	+	+	+	+	+	+	+			LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+				+	+	+	+	+	+	+	+	+	+	+	+			LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+				+			+	+	+	+	+	+	+	+	+	+	+	+			LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ6		+	+	+	+	+	+	+	+	+	+	+	+	+	DR103,DR12,DR51,DQ4 >	LMX

Table 38. Summary of the 539th Serum Exchange (Serum #1149-1152) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
7 typing Labs			7 typing Labs			7 typing Labs			7 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B44	86%	70%	B44	86%	90%	B44	71%	92%	B44	71%	92%
B45	43%	100%	B49	71%	100%	B45	57%	100%	B45	43%	75%
B49	29%	33%	B45	71%	60%	A29	14%	100%	B12	14%	100%
B12	14%	100%	B50	57%	100%	A9	14%	100%	B21	14%	100%
B21	14%	100%	B62	57%	100%	B12	14%	100%	B27	14%	100%
B50	14%	100%	B72	43%	100%	B21	14%	100%			
			B35	29%	100%						
			B71	29%	100%						
			B12	14%	100%						
			B21	14%	100%						
			B27	14%	100%						
			B52	14%	100%						
			B75	14%	100%						

Method: NIH-Extended											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B44	100%	93%	B35	100%	100%	B45	100%	100%	B45	100%	100%
B45	100%	80%	B45	100%	100%	B44	100%	97%	B44	100%	90%
B49	67%	100%	B49	100%	100%	B49	33%	100%	B41	33%	100%
B47	33%	100%	B62	100%	100%	B50	33%	100%	B49	33%	100%
B41	33%	67%	B44	100%	97%				B60	33%	100%
			B50	67%	100%						
			B71	67%	100%						
			B72	67%	100%						
			B41	33%	100%						
			B53	33%	100%						
			B75	33%	100%						
			B51	33%	83%						
			B52	33%	50%						

Table 39. Summary of the 539th Serum Exchange (Serum #1149-1152) by Antiglobulin and Other - class I

Method: Antiglobulin											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
4 typing Labs			4 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B44	100%	100%	B35	100%	100%	B44	100%	100%	B44	100%	100%
B45	100%	100%	B44	100%	100%	B45	100%	100%	B45	100%	100%
B49	100%	100%	B49	100%	100%	B49	100%	100%	B50	100%	100%
B50	100%	100%	B50	100%	100%	B50	100%	57%	B60	100%	100%
B60	100%	100%	B45	75%	100%	A24	50%	67%	B49	100%	90%
B61	100%	90%	B62	75%	100%	B60	50%	67%	B61	100%	90%
B41	75%	100%	B71	50%	100%	B61	50%	67%	B41	75%	100%
A66	25%	100%	B72	50%	100%	A23	25%	100%	B13	50%	100%
B13	25%	100%	B78	50%	100%	B13	25%	100%	A66	25%	100%
B47	25%	100%	A31	25%	100%	B41	25%	100%	B47	25%	100%
B51	25%	77%	A66	25%	100%	B71	25%	100%	B64	25%	100%
B42	25%	67%	B13	25%	100%	A1	25%	91%	B62	25%	80%
			B18	25%	100%	B37	25%	50%			

Method: Other											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
3 typing Labs			3 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	67%	100%	B12C	33%	100%	A1	50%	100%	A1	50%	100%
B13	67%	100%	B35	33%	100%	A23	50%	100%	B12C	50%	100%
B41	67%	100%	B45	33%	100%	A24	50%	100%	B13	50%	100%
B44	67%	100%	B53	33%	100%	A25	50%	100%	B15	50%	100%
B45	67%	100%	B5C	33%	100%	A32	50%	100%	B18	50%	100%
B47	67%	100%	B62	33%	100%	A34	50%	100%	B35	50%	100%
B49	67%	100%	B72	33%	100%	B12C	50%	100%	B41	50%	100%
B50	67%	100%	B75	33%	100%	B44	50%	100%	B44	50%	100%
B60	67%	100%	B77	33%	100%	B45	50%	100%	B45	50%	100%
B61	67%	100%	B7C	33%	100%	B5C	50%	100%	B47	50%	100%
A32	33%	100%	B8C	33%	100%	B60	50%	100%	B49	50%	100%
B12C	33%	100%				B7C	50%	100%	B50	50%	100%
B27	33%	100%				BW4	50%	100%	B60	50%	100%
B35	33%	100%							B61	50%	100%
B46	33%	100%							B70	50%	100%
B51	33%	100%									

Table 40. Summary of the 539th Serum Exchange (Serum #1149-1152) by Luminex - class I

*** Serum 1149 ***		
30 typing Labs		
Antigen	Consensus	Inclusion
B41	97%	100%
B44	93%	100%
B45	93%	100%
B47	93%	100%
B50	93%	100%
A2	93%	96%
B60	90%	100%
B49	87%	100%
CW4	87%	100%
CW6	87%	100%
B35	87%	86%
A32	83%	100%
B13	83%	100%
CW15	83%	100%
B61	83%	38%
B62	80%	100%
CW17	80%	100%
CW18	80%	100%
CW2	80%	100%
CW5	80%	100%
B27	77%	100%
B46	77%	100%
B76	77%	100%
CW8	77%	100%
B56	73%	100%
CW12	73%	100%
CW9	73%	100%
B72	73%	83%
B53	73%	80%
B58	73%	80%
B51	70%	100%
B57	70%	100%
CW10	70%	100%
B82	67%	100%
B52	63%	100%
B63	63%	100%
B75	63%	100%

*** Serum 1150 ***		
30 typing Labs		
Antigen	Consensus	Inclusion
B45	100%	100%
B35	97%	100%
B18	93%	100%
B60	93%	100%
B41	90%	100%
B49	90%	100%
B53	90%	100%
B61	90%	100%
B62	90%	100%
B72	90%	100%
B44	87%	100%
B48	87%	100%
B50	87%	100%
B75	87%	100%
B52	83%	100%
B56	83%	100%
B51	83%	90%
B13	80%	100%
B37	80%	100%
B47	80%	100%
B76	80%	100%
B38	77%	100%
B71	77%	100%
B77	77%	100%
B78	77%	100%
B63	73%	83%
B57	73%	78%
B46	70%	100%
B65	70%	67%
B59	67%	80%
B39	63%	100%
B58	63%	100%
B64	63%	100%
B8	63%	100%
B82	50%	100%
CW10	33%	100%
CW9	32%	100%

*** Serum 1151 ***		
29 typing Labs		
Antigen	Consensus	Inclusion
A23	97%	100%
A24	93%	100%
B41	93%	100%
B45	93%	100%
B47	93%	100%
B50	93%	100%
B44	93%	50%
B60	90%	100%
B61	90%	100%
B13	83%	100%
A1	79%	100%
B49	79%	100%
B76	79%	100%
A80	72%	100%
B27	69%	100%
A32	69%	71%
B38	66%	100%
B77	66%	100%
B82	66%	100%
A25	66%	75%
B75	66%	50%
B58	62%	100%
B64	62%	100%
A34	62%	50%
B51	59%	100%
B55	59%	100%
B56	59%	100%
B57	59%	100%
B59	59%	100%
B63	59%	100%
B7	59%	100%
A43	55%	100%
B37	55%	100%
B52	55%	100%
B81	52%	100%
CW4	48%	100%
B53	45%	100%

*** Serum 1152 ***		
29 typing Labs		
Antigen	Consensus	Inclusion
B44	100%	100%
B41	97%	100%
B47	97%	100%
B13	93%	100%
B49	93%	100%
B50	93%	100%
B60	93%	100%
B61	93%	100%
B45	90%	100%
B62	90%	67%
B76	79%	100%
B46	76%	80%
B71	76%	80%
B72	76%	67%
B75	72%	88%
B35	72%	71%
A23	69%	100%
B82	69%	100%
B73	69%	60%
B48	66%	80%
B18	66%	57%
CW1	62%	100%
CW12	62%	100%
CW8	62%	100%
CW9	62%	100%
A1	62%	75%
B64	62%	60%
CW10	59%	100%
CW16	59%	100%
A24	59%	71%
B78	52%	50%
CW14	45%	100%
B39	45%	75%
CW7	48%	100%
A34	31%	50%
B8201	24%	100%
A31	21%	100%

Table 41. Summary of the 539th Serum Exchange (Serum #1149-1152) by Flow Cytometry - class I

Method: Flow Cytometry											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	50%	100%	BW4	50%	100%	A1	50%	100%	A23	50%	100%
A25	50%	100%	BW6	50%	83%	A23	50%	100%	A24	50%	100%
A29	50%	100%				A24	50%	100%	A30	50%	100%
A3	50%	100%				A25	50%	100%	A34	50%	100%
A32	50%	100%				A29	50%	100%	B13	50%	100%
B13	50%	100%				A32	50%	100%	B18	50%	100%
B18	50%	100%				A34	50%	100%	B35	50%	100%
B27	50%	100%				B13	50%	100%	B39	50%	100%
B35	50%	100%				B27	50%	100%	B41	50%	100%
B41	50%	100%				B38	50%	100%	B44	50%	100%
B44	50%	100%				B41	50%	100%	B45	50%	100%
B45	50%	100%				B42	50%	100%	B46	50%	100%
B47	50%	100%				B44	50%	100%	B47	50%	100%
B48	50%	100%				B45	50%	100%	B48	50%	100%
B49	50%	100%				B47	50%	100%	B49	50%	100%
B50	50%	100%				B49	50%	100%	B50	50%	100%
B51	50%	100%				B50	50%	100%	B60	50%	100%
B52	50%	100%				B52	50%	100%	B61	50%	100%
B53	50%	100%				B57	50%	100%	B62	50%	100%
B56	50%	100%				B60	50%	100%	B64	50%	100%
B57	50%	100%				B61	50%	100%	B71	50%	100%
B58	50%	100%				B7	50%	100%	B72	50%	100%
B59	50%	100%				B75	50%	100%	B73	50%	100%
B60	50%	100%				B76	50%	100%	B75	50%	100%
B61	50%	100%				B77	50%	100%	B76	50%	100%
B62	50%	100%				B82	50%	100%	B82	50%	100%
B72	50%	100%									
B75	50%	100%									
B76	50%	100%									
B77	50%	100%									
B82	50%	100%									

Table 42. Summary of the 539th Serum Exchange (Serum #1149-1152) by Elisa and C1q - class I

Method: Elisa											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B13	100%	100%	B13	100%	100%	B13	100%	100%	B13	100%	100%
B49	100%	100%	B41	100%	100%	B44	100%	100%	B41	100%	100%
B44	100%	75%	B44	100%	100%	B45	100%	100%	B44	100%	100%
A1	50%	100%	B45	100%	100%	B49	100%	100%	B60	100%	100%
A32	50%	100%	B49	100%	100%	B60	100%	100%	B75	100%	100%
B35	50%	100%	B75	100%	100%	A1	50%	100%	A23	50%	100%
B41	50%	100%	B18	50%	100%	A23	50%	100%	B39	50%	100%
B45	50%	100%	B35	50%	100%	A29	50%	100%	B45	50%	100%
B46	50%	100%	B37	50%	100%	B41	50%	100%	B46	50%	100%
B47	50%	100%	B38	50%	100%	B46	50%	100%	B47	50%	100%
B50	50%	100%	B39	50%	100%	B47	50%	100%	B49	50%	100%
B53	50%	100%	B47	50%	100%	B50	50%	100%	B50	50%	100%
B60	50%	100%	B48	50%	100%	B58	50%	100%	B61	50%	100%
B61	50%	100%	B50	50%	100%	B59	50%	100%	B62	50%	100%
B75	50%	100%	B51	50%	100%	B61	50%	100%	B63	50%	100%
CW10	50%	80%	B52	50%	100%	B63	50%	100%	CW1	50%	100%
A74	50%	50%	B53	50%	100%	B76	50%	100%	CW10	50%	100%
B51	50%	50%	B56	50%	100%	A24	50%	50%	B72	50%	50%
B57	50%	50%	B59	50%	100%	A32	50%	50%			

Method: C1q											
*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

Table 43 . Summary of the 539th Serum Exchange (Serum #1149-1152) by NIH-Standard, Other, and C1q - class II

Method: NIH-Standard

*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no antigens assigned			no consensus			no antigens assigned		

Method: Other

*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: C1q

*** Serum 1149 ***			*** Serum 1150 ***			*** Serum 1151 ***			*** Serum 1152 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no consensus			no consensus			no antigens assigned		

Table 44. Summary of the 539th Serum Exchange (Serum #1149-1152) by Luminex - class II

*** Serum 1149 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DQ8	85%	100%
DQ9	85%	88%
DQ7	85%	81%
DR10	15%	100%
DR7	15%	100%

*** Serum 1150 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DR1	100%	91%
DR7	90%	100%
DR10	90%	80%
DR103	80%	80%
DR9	80%	64%
DR53	75%	57%
DR51	70%	69%
DQ6	20%	100%
DR4	20%	100%
DQ5	20%	100%
DR15	20%	100%

*** Serum 1151 ***		
18 typing Labs		
Antigen	Consensus	Inclusion
DQ5	100%	100%
DQ6	94%	100%
DR1	94%	100%
DR10	94%	100%
DR9	94%	100%
DR103	89%	100%
DQ2	89%	96%
DR51	83%	100%
DR4	78%	69%
DR16	78%	100%
DPW1	72%	100%
DPW5	72%	100%
DR15	72%	100%
DP17	67%	100%
DPW3	67%	100%
DP13	61%	100%
DP14	61%	100%
DP15	61%	100%
DP18	61%	100%
DPW6	61%	100%
DP10	56%	100%
DP11	56%	100%
DP9	56%	100%
DR14	56%	33%
DR18	22%	100%
DR52	22%	100%
DQ4	17%	100%
DQ9	17%	100%
DR11	17%	100%

*** Serum 1152 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DR7	100%	100%
DR9	100%	100%

Table 45. Individual laboratory results for Serum #1149-1152 by NIH-Standard and NIH-Extended

Investigator	**** Serum 1149 ****								**** Serum 1150 ****														**** Serum 1151 ****							**** Serum 1152 ****							Method				
	% POS	B44	B45	B49	B12	B21	B50	Other	% POS	B44	B49	B45	B50	B62	B72	B35	B71	B12	B21	B27	B52	B75	Other	% POS	B44	B45	A29	A9	B12	B21	Other	% POS	B44	B45	B12	B21		B27	Other		
Claas, F.H.J.	24	+						64	+	+		+	+	+	+					+	+			48	+		+					28	+					+		STD	
Fort, Marylise	14	+	+						+	+	+	+	+	+	+		+																							STD	
Hogan, Patrick		+							+	+	+		+													+	+														STD
McCluskey, James	21	+	+	+				25	+	+	+													15	+	+						18	+	+							STD
Reed, Elaine F. PhD	20	+	+	+			+	50	+	+	+	+	+	+			+						15	+	+						16	+	+								STD
Suciu-Foca, Nicole I	17				+	+		61								+		+	+				58				+	+	+		17			+	+					STD	
Watson, Narelle	16	+						38	+	+	+	+											30	+	+						29	+	+								STD

Investigator	**** Serum 1149 ****								**** Serum 1150 ****														**** Serum 1151 ****							**** Serum 1152 ****							Method				
	% POS	B44	B45	B49	B47	B41		Other	% POS	B35	B45	B49	B62	B44	B50	B71	B72	B41	B53	B75	B51	B52	Other	% POS	B45	B44	B49	B50	Other	Other	% POS	B45	B44	B41	B49	B60		Other			
Askar, Medhat Z. M	43	+	+	+		+		60	+	+	+	+	+	+	+		+						29	+	+						46	+	+	+	+	+				EXT	
Dunn, Paul	30	+	+	+				48	+	+	+	+	+		+	+				+	+	+		29	+	+					20	+	+								EXT
Lardy, N.M.	23	+	+		+			62	+	+	+	+	+	+	+	+		+					30	+	+	+	+				23	+	+								EXT

Table 46. Individual laboratory results for Serum #1149-1152 by Antiglobulin and Other

**** Serum 1149 ****													**** Serum 1150 ****													Method
Investigator	% POS	B44	B45	B49	B50	B60	B61	B41					Other	% POS	B35	B44	B49	B50	B45	B62	B71	B72	B78	Other		
Cecka, J. Michael P	47	+	+	+	+	+	+	+					A66,B13,B47,B42	50	+	+	+	+	+	+	+	+	+	B41	Antiglobulin	
Hahn, Amy B. PhD		+	+	+	+	+	+	+					B51		+	+	+	+	+				+	B51,B53	Antiglobulin	
Mah, Helen	48	+	+	+	+	+	+	+						62	+	+	+	+		+	+	+		A24,B60,A66,B13 >	Antiglobulin	
Suciu-Foca, Nicole I	20	+	+	+	+	+	+							55	+	+	+	+	+	+				B70	Antiglobulin	

**** Serum 1151 ****													**** Serum 1152 ****													Method
Investigator	% POS	B44	B45	B49	B50	A24	B60	B61					Other	% POS	B44	B45	B50	B60	B49	B61	B41	B13			Other	
Cecka, J. Michael P	30	+	+	+	+		+	+					B37,B41,B71	45	+	+	+	+	+	+	+	+			A66,B47	Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+							A1		+	+	+	+	+	+	+					Antiglobulin
Mah, Helen	24	+	+	+	+									48	+	+	+	+	+	+	+	+			B62,B64	Antiglobulin
Suciu-Foca, Nicole I	40	+	+	+	+	+	+	+					B13,A23	15	+	+	+	+	+	+						Antiglobulin

**** Serum 1149 ****													**** Serum 1150 ****													Method
Investigator	% POS	A2	B13	B41	B44	B45	B47	B49	B50	B60	B61		Other	% POS	B12C	B35	B45	B53	B5C	B62	B72	B75	B77	Other		
Phelan, Donna		+											12C,B5C		+				+						B7C,B8C	Other
Reed, Elaine F. PhD			+	+	+	+	+	+	+	+	+					+	+	+		+	+	+	+			Other
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+		A32,B27,CW4,CW6,B62 >													Other

**** Serum 1151 ****													**** Serum 1152 ****													Method
Investigator	% POS	A1	A23	A24	A25	A32	A34	B12C	B44	B45	B5C	B60	Other	% POS	A1	B12C	B13	B15	B18	B35	B41	B44	B45	B60	Other	
Phelan, Donna		+	+	+	+	+	+	+			+		BW4,B7C		+	+		+	+	+					B70	Other
Reed, Elaine F. PhD									+	+		+					+				+	+	+	+	B47,B49,B50,B61	Other
Rosen-Bronson, Sa																										Other

Table 47. Individual laboratory results for Serum #1149 by Luminex

		**** Serum 1149 ****																																					
Investigator	% POS	B41	B44	B45	B47	B50	A2	B60	B49	CW4	CW6	B35	A32	B13	CW15	B61	B62	CW17	CW18	CW2	CW5	B27	B46	B76	CW8	B56	CW12	CW9	B72	B53	B58	B51	B57	CW10	Other	Method			
Alvarez, Carretto &	34	+	+	+	+	+	+		+	+	+	+		+	+			+	+	+	+			+	+		+									A24,B40,B82,CW3	LMX		
Askar, Medhat Z. M	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B52,B75,A25 >	LMX		
Askar/WV,	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX		
Brouard, Tabary/Ph	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B52,B75,A29 >	LMX		
Cecka, J. Michael P	73	+	+	+	+	+	+	+				+	+	+		+	+						+	+	+		+			+	+	+	+	+	B82,B73	LMX			
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX		
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A203,A66,B78 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B78,B52 >	LMX		
Gideoni, Osnat	82	+	+	+	+	+	+	+	+				+	+	+	+	+									+				+	+	+	+	+	+	B48,B78,B52,B82 >	LMX		
Guerra, Q.F.B. Elba		+					+	+		+	+	+															+								A80,BW4,CW3	LMX			
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX		
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B75,B63,BW4 >	LMX	
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B82,B63 >	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A203,B78,B52 >	LMX	
Klein, Tirza	34	+	+	+	+	+	+			+	+	+				+			+	+	+	+				+										A24,B40,B15,A23 >	LMX		
Lardy, N.M.		+	+	+	+	+		+	+	+	+					+	+		+	+	+	+			+	+				+					+	B8201	LMX		
Loewenthal MD, Ro	86	+	+	+	+	+	+	+	+				+	+		+	+							+	+							+	+			B52,B82,A25,A26 >	LMX		
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A203,B52,B75 >	LMX	
Mani, Rama	78						+	+		+	+	+	+		+																					A25,A29,A33,A80 >	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX	
Meyer, Pieter Wa	25	+	+	+	+	+	+			+		+				+			+	+	+	+															A24,B40,B15,A66 >	LMX	
Pancoska, Carol Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B52,B82,B75,B63 >	LMX	
Permpikul, Vejbaesy		+	+	+	+	+		+	+		+	+	+	+	+	+	+	+						+													A24,B52,B75,A1 >	LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B52,B75,B63,B59 >	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B78,B52,B82,B75 >	LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B75,B63,B59 >	LMX
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B52,B75,B67,A25 >	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B82,B2708	LMX

Table 48. Indirect results for Serum #1150 by Luminex

		**** Serum 1150 ****																																					
Investigator	% POS	B45	B35	B18	B60	B41	B49	B53	B61	B62	B72	B44	B48	B50	B75	B52	B56	B51	B13	B37	B47	B76	B38	B71	B77	B78	B63	B57	B46	B65	B59	B39	B58	B64	B8	Other	Method		
Alvarez, Carretto &	31	+	+	+	+			+	+	+	+	+	+	+	+		+			+	+	+				+												B82	LMX
Askar, Medhat Z. M	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW10,CW9,B7801,B8201 >	LMX	
Askar/WV,	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX		
Brouard, Tabary/Ph	75	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7801,B8201,B3901	LMX		
Cecka, J. Michael P	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,B82,CW10,CW9	LMX		
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,CW10,CW9,CW5	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	BW4,B8201	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,B27,B82,B54 >	LMX		
Gideoni, Osnat	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B54,A34,A29 >	LMX		
Guerra, Q.F.B. Elba		+					+	+			+																									A29,A30,A31,A3 >	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,CW10,CW9	LMX		
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	BW4,BW6	LMX	
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B54	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A24,B27,B82 >	LMX	
Klein, Tirza	82	+	+	+	+	+	+		+	+	+		+	+	+	+	+	+	+						+												B42,B73,B7801	LMX	
Lardy, N.M.		+	+	+	+	+		+	+	+	+	+			+							+					+										B82	LMX	
Loewenthal MD, Ro	94	+	+	+	+	+	+	+	+	+		+		+		+		+	+							+			+	+				+			A2,A66,B82,B54 >	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B27,B55,A32 >	LMX	
Mani, Rama	90	+	+		+		+																														CW6,A2,A30,CW3 >	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Meyer, Pieter Wa	19	+	+	+		+						+	+				+				+						+								+		B40,B15,B82	LMX	
Pancoska, Carol Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A30,A31,A33 >	LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7801,B8201,B3901	LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A25 >	LMX	
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,CW10,CW9,B8201 >	LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7801,B3901	LMX	

Table 50. Indirect results for Serum #1152 by Luminex

Investigator	**** Serum 1152 ****																											Method											
	% POS	B44	B41	B47	B13	B49	B50	B60	B61	B45	B62	B76	B46	B71	B72	B75	B35	A23	B82	B73	B48	B18	CW1	CW12	CW8	CW9	A1		B64	CW10	CW16	A24	B78	CW14	B39	CW7	Other		
Alvarez, Carretto &	26	+	+	+	+	+	+	+	+	+		+							+																				LMX
Askar, Medhat Z. M	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	A34,B77,B7801,B8201 >	LMX		
Askar/WV,	88	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B77	LMX	
Brouard, Tabary/Ph	55	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		B7801,B8201,B3901	LMX		
Cecka, J. Michael P	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+										LMX	
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		A34	LMX	
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,A34,A31,B65 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX		
Fort, Marylise																																						LMX	
Gideoni, Osnat	64	+	+	+	+	+	+	+	+	+	+		+		+	+			+	+	+														+	B54,A74,A36,A80 >	LMX		
Guerra, Q.F.B. Elba		+		+										+				+																	+	A31,A32,B38,B37 >	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34	LMX
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,BW4,BW6	LMX
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+						+	+																		A68,CW18	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B27,A34,A30 >	LMX	
Klein, Tirza	60	+	+	+	+	+	+	+	+	+	+		+		+																						B54,B8101,B8201	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+							+																			LMX	
Loewenthal MD, Ro	86	+	+	+	+	+	+	+	+	+	+			+				+	+	+		+													+	A66,B54,A31,A32 >	LMX		
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	B27,A34,A30,A31 >	LMX	
Mani, Rama	52	+	+						+			+																									CW6,A80	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,A34,A31,B65 >	LMX
Meyer, Pieter Wa	18	+	+	+	+				+									+	+																	+	B40,B15,A68,CW18	LMX	
Pancoska, Carol Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+									+											CW6,A30,CW2,CW5	LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A34,B7801,B8201,B3901	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B27,B77,B8201,B3901	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8201	LMX

Table 51. Individual laboratory results for Serum #1149-1152 by Flow Cytometry

		**** Serum 1149 ****																	**** Serum 1150 ****																						
Investigator	% POS	A2	A25	A29	A3	A32	B13	B18	B27	B35	B41	B44	B45	B47	B48	B49	B50	B51	B52	Other	% POS	BW4	BW6																	Other	Method
Eckels/CPMC,	99																				96																		FC		
Esteves Kondo, Det	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61>	94	+	+																FC		

		**** Serum 1151 ****																	**** Serum 1152 ****																				
Investigator	% POS	A1	A23	A24	A25	A29	A32	A34	B13	B27	B38	B41	B42	B44	B45	B47	B49	B50	B52	Other	% POS	A23	A24	A30	A34	B13	B18	B35	B39	B41	B44	B45	B46	B47	B48	B49	B50	Other	Method
Eckels/CPMC,	95																				88																		FC
Esteves Kondo, Det	75	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61>	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61 >	FC

Table 52. Individual laboratory results for Serum #1149-1152 by Elisa and C1q

		**** Serum 1149 ****													**** Serum 1150 ****																	
Investigator	% POS	B13	B49	B44	A1	A32	B35	B41	B45	B46	B47	B50		Other	% POS	B13	B41	B44	B45	B49	B75	B18	B35	B37	B38	B39	B47	B48	B50	Other	Method	
Esteves Kondo, Det	69	+	+	+	+	+	+	+	+	+	+	+		B75,A74,B57,CW10	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2	Elisa
Hahn, Amy B. PhD		+	+	+		+	+	+	+	+	+	+		B60,B61,B51,B53		+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61,B78,B62 >	Elisa	

		**** Serum 1151 ****													**** Serum 1152 ****															
Investigator	% POS	B13	B44	B45	B49	B60	A1	A23	A29	B41	B46	B47	B50	Other	% POS	B13	B41	B44	B60	B75	A23	B39	B45	B46	B47	B49	B50		Other	Method
Esteves Kondo, Det	57	+	+	+	+	+					+			B76	57	+	+	+	+	+	+								CW1,CW10	Elisa
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+		+	+	A24,B61,B51,B53 >		+	+	+	+	+		+	+	+	+	+	+		B61,B62,B63,B72	Elisa

		**** Serum 1149 ****													**** Serum 1150 ****																	
Investigator	% POS	B13	B41	B44	B45	B47	B49	B50	B60	B61	B76	B82		Other	% POS	B44	B49	B50	B62	B72	B75	B76								Other	Method	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+		CW6,CW2,CW5,CW17 >		+	+	+	+	+	+	+										C1q

		**** Serum 1151 ****													**** Serum 1152 ****																
Investigator	% POS	A1	A23	A24	B13	B41	B44	B45	B47	B49	B50	B60	B61	Other	% POS	B13	B41	B44	B45	B47	B49	B50	B60	B61	B76				Other	Method	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	B76,B62		+	+	+	+	+	+	+	+	+	+						C1q

Table 53. Individual laboratory results for Serum #1149-1152 by NIH-Standard, Other, and C1q - class II

	**** Serum 1149 ****						**** Serum 1150 ****					**** Serum 1151 ****										**** Serum 1152 ****										
Investigator	% POS	no antigens assigned					no antigens assigned					% POS	DR1															Other	% POS	no antigens assigned		Method
Clas, F.H.J.												48	+																			STD

	**** Serum 1149 ****							**** Serum 1150 ****					**** Serum 1151 ****										**** Serum 1152 ****							
Investigator	% POS	DR4	DQ3	DQ7	DQ8	DQ9	Other	% POS	DR1	DR103	DR51	DR7	Other	% POS	DR1	DR10	DR14	DR15	DR16	DR51	DR9	DQ5	DQ6		Other	% POS	DR7	DR9	Other	Method
Phelan, Donna		+	+	+	+	+			+	+	+	+			+	+	+	+	+	+	+	+	+				+	+		Other

	**** Serum 1149 ****						**** Serum 1150 ****				**** Serum 1151 ****										**** Serum 1152 ****							
Investigator	% POS	no antigens assigned					% POS	DQ4	DQ8	Other		% POS	DR1	DR10	DR103	DR51	DR9	DPW1	DPW5	DPW6	DQ5	DQ6	Other	% POS	no antigens assigned		Method	
Phelan, Donna								+	+				+	+	+	+	+	+	+	+	+	+						C1q

Table 54. Individual laboratory results for Serum #1149-1150 by Luminex - class II

Investigator	**** Serum 1149 ****							**** Serum 1150 ****															Method
	% POS	DQ8	DQ9	DQ7	DR10	DR7	Other	% POS	DR1	DR7	DR10	DR103	DR9	DR53	DR51	DQ6	DR4	DQ5	DR15	Other			
Askar, Medhat Z. M	99	+	+	+				96	+	+	+	+	+	+	+							LMX	
Askar/WV,	95	+	+	+				97	+	+	+	+	+	+	+							LMX	
Cecka, J. Michael P	73	+	+	+				80	+	+	+	+	+	+	+							LMX	
Chen, Dong-Feng		+	+	+					+	+	+	+	+	+	+							LMX	
Eckels/CPMC,		+	+	+					+	+	+	+	+	+	+							LMX	
Fort, Marylise		+	+	+			DQ2,DQ4		+	+	+	+	+	+	+	+	+					LMX	
Guerra, Q.F.B. Elba		+	+	+	+		DR14		+	+	+											LMX	
Hahn, Amy B. PhD		+	+	+					+	+	+	+	+	+								LMX	
Hogan, Patrick					+	+	DR9,DR53,DQ3		+	+	+		+	+		+	+	+	+		DR3,DR11,DR16,DR52 >	LMX	
Holdsworth, Rhonda		+	+	+					+	+	+	+	+	+								LMX	
Klein, Tirza	34					+	DR15,DR16	82	+							+	+	+			DR16,DQ4,DQ7	LMX	
Mani, Rama	78	+	+	+				90	+		+	+		+							+	LMX	
Meyer, Pieter Wa	25						DQ3	19	+	+	+		+			+	+	+			DQ3,DQ4	LMX	
Pancoska, Carol Ph		+	+	+					+	+	+	+	+	+	+							LMX	
Permpikul, Vejbaesy		+	+	+			DR103,DR4,DR14,DPW5		+	+	+	+	+							+	DQ2	LMX	
Phelan, Donna		+	+	+					+	+		+			+							LMX	
Ramon, Daniel PhD		+	+	+	+	+	DR9,DR53,DQ2		+	+	+	+	+	+	+							LMX	
Rosen-Bronson, Sai		+	+	+					+	+	+	+	+	+	+							LMX	
Turner, E.V. PhD		+	+	+					+	+	+	+	+	+	+							LMX	
Vather, Nelson/		+	+	+					+	+	+	+	+	+	+							LMX	

Table 55. Individual laboratory results for Serum #1151-1152 by Luminex - class II

Investigator	**** Serum 1151 ****																				**** Serum 1152 ****				Method										
	% POS	DQ5	DQ6	DR1	DR10	DR9	DR103	DQ2	DR51	DR4	DR16	DPW1	DPW5	DR15	DP17	DPW3	DP13	DP14	DP15	DP18	DPW6	DP10	DP11	DP9		DR14	DR18	DR52	Other	% POS	DR7	DR9	Other		
Askar, Medhat Z. M	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR12,DR17	97	+	+		LMX		
Askar/WV,	95	+	+	+	+	+	+	+	+	+	+	+	+	+		+						+				+	+		88	+	+		LMX		
Cecka, J. Michael P	60	+	+	+		+	+	+	+	+																			45	+	+		LMX		
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX
Fort, Marylise																																			LMX
Guerra, Q.F.B. Elba		+	+	+	+		+	+							+	+	+	+	+	+	+	+	+	+			+	DR53,DQ4,DQ7,DQ9			+	+		LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+		+	+	+		+	+	+	+	+	+	+	+	+								+	+		LMX	
Hogan, Patrick		+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+							+	DR11,DQ3			+	+		LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		DR12,DR17			+	+	DR10	LMX	
Klein, Tirza	64	+	+	+	+	+					+	+																	60	+	+		LMX		
Mani, Rama	70	+	+	+	+	+	+	+	+	+																+	+	+	DR11,DR13,DQ4,DQ7 >	52	+	+	DQ5	LMX	
Meyer, Pieter Wa	14	+	+	+	+	+		+		+	+			+														DR3	18	+	+		LMX		
Pancoska, Carol Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						+	+		LMX	
Permpikul, Vejbaesy		+		+	+	+	+		+	+	+	+	+	+	+				+							+	DR7,DR8,DR11,DR13 >			+	+	DQ2	LMX		
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX	
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX	
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+	+		LMX	
Vather, Nelson/																															+	+		LMX	